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ETHANOL, CATECHOI.AMINES AND ALKALOIDS: 
INTERFACE Of NEUROCHEMISTRY AND ALCOHOLISM 
The theory has been advanced that tetrahydroisoquinoline (TIQ) 
alkaloids may form in neuronal and chrornaffin cells during alcohol metab-
olism via condensation of catecholamines (CAs) and alcohol-derived 
aldehydes. The cyclic CA-type alkaloids could assume a physiological 
role in the development of alcohol dependence (G.Cohen and M. Collins, 
Science 167: 1749-1751). 
As groundwork for in vivo studies on TIQs during alcoholism, the 
following questions required study. 
(1) What are suitable chronic alcoholic animal models for the 
investigation of TIQ formation and CA changes? 
(2) What are the possible products of catabolism of TIQs? Can the 
catabolism of TIQs be blocked through methods similar to those used to 
inhibit catabolism of endogenous amines? 
(3) What pharmacological methods can be employed to maximize TIQ 
formation in vitro and i~ viv~? What are the effects of these methods on 
the enzymes of ethanol and acetaldehyde metabolism? 
In the studies with chronic alcoholic animal models, mice and 
rabbits were provided with liquid Metrecal/ethanol (EtOH) diets as the 
sole sources of food. This protocol produced intoxication and slight 
alcohol withdrawal symptoms in the mice, agreeing somewhat with the 
results of G. Freund (Arch. Neurol. 21: 315, 1969). Rabbits falMetrecal/ 
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ethanol for 80 days displayed negligible signs of intoxication, despite 
developing substantial blood EtOH and occasionally high blood acetal-
dehyde (AcD) concentrations. Fatty liver changes were demonstrated. 
Malnutritional aspects of this diet were possible factors contributing 
to the pathologies seen. 
4-Hydroxylated TIQ alkaloids derived from the neurotransmitter 
NE and AcD or formaldehyde were found to be readily 0-methylated in 
vitro in rat brain and liver homogenates. Since it was significantly 
inhibited by pyrogallol (PG; 1,2,3-trihydroxybenzene), the catechol 
alkaloid 0-methylation was due in part to the same enzyme that catabol-
izes the endogenous CAs, catechol-0-methyltransferase (COMT). Brain 
COMT 0-methylated the TIQ alkaloids and NE to similar degrees, but liver 
COMT 0-methylated the TIQs to a significantly greater extent than NE in 
these experiments. Furthermore, there was no evidence for monoamine 
oxidase action on the cyclic alkaloids, although the open-chain NE pre-
cursor did produce oxidation products. 
PG was found to have a novel effect on AcD and its metabolism. 
Rats treated with PG prior to EtOH intoxication demonstrated signifi-
cantly higher blood AcD levels than did non-PG-treated, intoxicated 
controls. It was determined in in vitro experiments that this effect 
was due in part to PG inhibition of liver aldehyde dehydrogenase (ALDH). 
Several other compounds structurally related to PG, notably the clin-
ically-important decarboxylase inhibitor R044602 (for Parkinsonism 
therapy), were found to inhibit ALDH iil vitro; this property may lead 
these or similar trihydroxy-benzene-containing drugs to clinical applica-
tion as disulfiram-like deterrents in human alcoholics. 
Thus PG was found to be potentially useful in enhancing TIQ 
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alkaloid levels in vivo through three biochemical mechanisms, two of 
which were demonstrated in these studies: (1) Oxidation of AcD via ALDH 
is inhibited and the concentration of one (AcD) of the two TIQ precursor 
molecules is maximized. (2) 0-Methylation (and possibly inactivation) 
of TIQs is decreased, favoring the isolation of catechol TIQs by alumina 
procedures currently in use. (3) Combined with the well-established 
inhibition of COMT by PG, which serves to maximize NE, epinephrine and 
dopamine (precursors of TIQs), effects (1) and (2) should lead to detec-
table TIQ levels during intoxication. In support of this, recent 
studies by Bigdeli in this laboratory (M. Bigdeli, Ph.D. Dissertation, 
Loyola University of Chicago, 1974) have shown that adrenal and brain 
CA-derived TIQs are detectable by gas chromatography when EtOH-int&xic-
ated rats are pretreated with PG. 
iv 
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PA...1lT ONE 
INTRODUCTION AND REVIEW OF THE LITERATURE 
A. BACKGROUND 
I. THEORIES OF ALCOHOL DEPENDENCE 
At present there is relatively poor consensus concerning an ad-
equate definition of alcoholism. As with most diseases that are express-
ed primarily as behavioral disorders, many social and environmental fac-
tors affect the definition of the problem. Perhaps the most widely 
accepted definition of alcoholism is that it is a disorder characterized 
by excessive drinking that results in injury to a person's health or ad-
equate social functioning or both (Mendelson, 1970). A number of inves-
tigators have employed specific pharmacologic criteria of addiction for 
selection and description of their research subjects. These pharmacol-
ogic criteria for alcohol addiction are the same as those employed for 
a variety of other addictive disorders--tolerance and physical dependence. 
Tolerance is demonstrated when, after repeated ingestion of a 
drug, increasing dosage must be used to give effects obtained in the 
original dose. Although there is tolerance observed in alcoholics, there 
is little evidence that altered EtOH metabolic processes can adequately 
account for the degree of tolerance that occurs. Cellular adaptation to 
EtOH has been advanced as a more parsimonious hypothesis to explain the 
phenomenon of tolerance (Mendelson, 1970). 
Axelrod (1968) has reviewed data relevant to the several mech-
anisms that may underlie cellular adaptation in the development of tol-
erance to drugs. Although the models he has described were based upon 
1 
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the possible action of narcotic analgesics, they have relevance for other 
centrally-acting drugs such as EtOH. Three possible factors are discuss-
ed: (1) reduced activity of the drug receptor, (2) depletion of endogenous 
substances that indirectly cause or mediate the drug action (transmitters), 
(3) enhanced metabolism or inactivation of the drug. There is much ev-
idence against the last of these factors with regard to EtOH. 
Axelrod (1956), studying morphine tolerance, has suggested that 
the first factor, drug-induced reduction of receptor-site activity, may 
cause the development of tolerance to that drug. These receptor sites 
may be enzymes, since liver N-demethylases, morphine catabolic enzymes, 
decrease in activity after continuous exposure to morphine. He postulat-
ed that a similar phenomenon might occur in the brain since the molecular 
structure of drug receptors in the central nervous system closely resem-
ble the N-demethylating enzymes in the liver microsomes. However, chal-
lengers to this theory have argued that development of tolerance to nar-
cotics can occur in rats without reduction of N-demethylating activity 
(Axelrod, 1956). In summary, Axelrod stresses the fact that isolation 
and characterization of analgesic receptors in the central nervous system 
are necessary precursomto testing hypotheses concerning reduction of 
receptor site activity by centrally acting analgesic drugs. 
The tolerance to EtOH may be mediated by endogenous putative 
transmitters, the second factor mentioned by Axelrod. There is some 
indirect evidence that this tolerance may be associated with a decreased 
release of acetylcholine. However, the findings of Gage (1965) indicate 
that EtOH acts to increase rather than to decrease the rate of transmitter 
release. This is consistent with neurophysiologic findings that alcohol 
depressed spinal cord reflexes without affecting synaptic transmitters. 
In line with these results are reports by Israel (1970) 1 that EtOH 
suppresses active transport of ions in nervous tissue by inhibiting 
Na+-K+-Mg++-- ATPases through competitive inhibition with potassium. 
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One of the major difficulties in exploring cellular adaptation in 
laboratory animals has been the surprising lack of effect of EtOH on a 
number of measurable indices when EtOH is administered in relatively 
physiologic concentrations. Suppression of several types of neurochemical 
and neurophysiologic activities has been reported with extraordinarily 
large doses of alcohol in in vitro systems. However, it has been dif-
ficult to ascertain an appreciable inhibition of cellular function when 
concentrations of EtOH are employed that produce inebriation rather than 
death (Israel, 1970). 
Goldstein and Goldstein (1968) have developed an enzyme repres-
sion theory of drug tolerance and physical dependence. This theory, 
which conceives of tolerance and physical dependence as a unitary mech-
anism, is based on the processes of repression and derepression of enzyme 
synthesis. In terms of an excitatory neuro-compound, for example NE, it 
is known that the synthesis of the ~E synthetic enzymes (NSE) is decreas-
ed by increased levels of NE, i.e. end-product repression. These authors 
postulate that inhibition of NSE activity by a drug such as EtOH would 
produce an immediate effect by decreasing the concentration of NE. This, 
in turn, would produce a depression of the NE excitatory function. Si-
multaneously, a decrease in end-product repression of NSE would result, 
i.e. derepression. As the concentratioIJSof enzyme NSE increased, more 
NE would be synthesized. In order to produce continued inhibition of 
NSE, more drug (EtOH) would be needed. This could explain ·the phenomenon 
of tolerance. Interestingly, chronic EtOH was seen to depress tyrosine 
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hydroxylase activity in rats, leading to depressed NE levels (Friedhoff, 
1972). 
In terms of physical dependence, it is thought that abrupt with-
drawal of a drug EtOH would result in a very large concentration of 
active enzyme NSE. This large conce.ntration of enzyme, in turn, would 
effect an enhanced synthesis of excitatory NE, and this great overproduc-
tion would have marked excitatory action (withdrawal symptoms). Thus, 
physical dependence results (Goldstein and Goldstein, 1968). 
Of course, the origin of the alcohol withdrawal syndrome is quite 
unclear, as are the critical determinants of the onset of withdrawal 
symptoms, since either a relative decrease in blood EtOH levels or an 
abrupt alcohol abstinence may precipitate this syndrome. Abstinence 
signs have been observed in subjects with blood alcohol levels as high 
as 100 mg/100 ml (Isbell et al, 1955). Withdrawal onset does not appear 
to be related to dosage or duration, since Mello and Mendelson (1970) 
have also observed partial withdrawal signs of tremors in subjects who 
have been drinking small amounts of alcohol for as little as four days. 
In chronically intoxicated alcoholic humans, many of whom have other 
associated pathologies, withdrawal symptoms can involve tremor, hallucina-
tions, and grand mal seizures, with a peak incidence 24 hours after the 
cessation of drinking. The syndrome of delirium tremors (D.T. 's), a 
state characterized by gross tremor and agitation, disorders of sense 
perception, and increased psychomotor and autonomic nervous system activ-
ity, has its onset between 72 and 96 hours following the cessation of 
drinking (Victor and Wolfe, 1973). Thus, two "subsyndromes" may follow 
EtOH withdrawal. 
EtOH toxicity and withdrawal symptoms may be due to (1) direct 
---
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actions of EtOH; (2) psychoendocrine factors, e.g. increased CA secretion 
and enhanced release of adrenocorticotrophic hormones can be induced by 
EtOH; or (3) through neurophysiologic "denervation supersensitivity," 
wherein EtOH may be causing a depression which is followed by a rebound 
super-excitation upon removal of the EtOH. This latter concept was 
noted by Jaffe and Sharpless (1968), since many withdrawal phenomena 
involve an exaggeration of behavior that is ordinarily suppressed by the 
agent that induces dependence. Finally, (4) EtOH may cause the formation 
of some new products, possibly alkaloids, that may play a part in the 
neurological aspects of withdrawal syndrome and physical dependence. 
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II. ETHANOL:METABOLISM 
"The sway of alcohol over mankind, 11 according to William James, 
"is unquestionably due to its power to stimulate the mystical facilities 
of human nature 11 (James, 1902). But mystical sway has been variously 
interpreted as having psychological, social, cOr biochemical bases, or 
combinations of these. The last, biochemical factors in alcoholism, has 
created intense interest in biomedical science of late. The study of 
alcohol and its related pathologies is vital to the betterment of over 
nine million Americans who have been classified as alcoholics. The origin 
of their affliction may be psychological or physical, if such a distinc-
tion can be made, and as such these heterogeneous persons are now label-
led as psychologically dependent and/or physically dependent, rather than 
by the older term of "addicted " (Mendelson, 1970). 
While it is generally recognized that ethyl alcohol is the chief 
intoxicant that innnediately affects one after he drinks commercial liquor, 
there are probably other chemicals involved. Chemicals used for coloring 
and taste purposes, called congeners, are known to have toxicities of 
their own, for example, in bourbon. Hangovers in the "morning after" 
have been suggested as stennning from alcohol-induced brain meningeal edema, 
or possibly from toxic glycol products of catecholamines (CAs) created by 
a metab9lic shift caused by EtOH (Smith and Gitlow, 1967). Others believe 
that increased diuresis, from suppression by EtOH of anti.diuretic hormone, 
is responsible for some of alcohol's effects. More specific evidence 
has recently pointed at acetaldehyde (AcD), the proximal metabolite of 
ethanol, as being at the root of some temporally later effects of EtOH 
as well as of some neurological aspects. 
The importance of AcD in the actions of EtOH as well as being 
--
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a factor in the etiology of alcoholism has been minimized in the past 
largely because of the relatively small amounts produced in the normal 
metabolism of alcohol. This appraisal has been based largely upon a 
limited amount of blood level data obtained by chemical methods which 
have been criticized recently for lack of specificity and sensitivity 
(Truitt and Duritz, 1967). Furthermore, AcD has been recognized as being 
directly responsible for a large number of actions in the acute and 
chronic intoxication syndromes produced by alcohol. AcD is a potent 
hypnotic in its own right, or in its tricyclic form of sustained release 
which is paraldehyde. In addition, it can induce nausea, vomiting, and 
sweating. It causes release of CAs and depression of oxidative phos-
phorylation in isolated brain tissue. Because the pharmacologic effects 
of AcD are generally subjectively unpleasant, it has been suggested that 
"while EtOH actions may be the reason that people drink alcohol, the 
actions of AcD may be more related to why they stop." (Truitt and Duritz, 
1967). 
8 
EtOH can be regarded as a drug as well as an oxidizable substrate. 
It acts as a general depressant, despite thebelavioial stimulation that is 
reflected in giddiness and increased activity. This pseudo-stimulation 
is most probably due to depression of inhibitory pathways in the brain. 
There seems to be fairly good agreement that most of the effects of EtOH 
as a depressant are not due to its metabolites but rather to the cellular 
effects of the alcohol molecule itself (Israel, 1970). 
As a group, general depressants have a high oil/water partition 
coefficient, and the relative potencies of depressants have a good 
correlation to their lipid solubility. This concept is correlated with 
the higher permeability of the blood-brain barrier for uncharged, lipo-
philic molecules. Pauling showed that the general depressants share the 
property of forming hydrated micro-crystals of the clathrate type 
(Pauling, 1961). These crystals would be formed by the depressant 
surrounded by water and the charged side group of proteins, and could 
conceivably prevent the catalytic activity of enzymes and other processes 
by increasing the rigidity of the molecule in the biological system. 
EtOH, as a depressant, should not be considered as a specific molecule, 
but rather should be classified in a larger group. It is, therefore, 
important to study the effects of other general depressants to determine 
whether they produce effects similar to those of EtOH by virtue of their 
depressant ability alone. 
EtOH is metabolized chiefly in the liver by alcohol dehydro-
genase (ADH) to form acetaldehyde (AcD). It is generally accepted that 
EtOH is not metabolized to any great extent in brain and that activity 
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of brain ADH is very low (Raskin and Sokoloff 1972). Until the recent 
interest in the microsomal ethanol-oxidizing system (MEOS), (Orme-Johnson 
and Ziegler, 1965), it was believed that ADH was the major, if not the 
exclusive, enzyme responsible for catalyzing 90-98% of the initial oxida-
tion of EtOH to AcD in liver. Hepatic ADH is a zinc-containing enzyme 
found mainly in the soluble fraction of the liver cell. It has a pH 
optimum of 10.4 and is NADtdependent. 
Recently, another hepatic enzyme system has been implicated as 
having a potent, important role in the oxidation of EtOH to AcD and 
methanol to formaldehyde. In 1965, Orme-Johnson and Ziegler described a 
hepatic MEOS that appeared similar to a variety of drug-metabolizing 
enzymes found in the liver. This microsomal oxidase system is dependent 
on NADPH and has a pH optimum of 7.2. Interestingly, chronic administra-
tion of EtOH to rats resulted in as much as a 200-fold increase in MEOS 
activity but with no significant increase in ADH activity (Lieber and De 
Carli, 1968). These authors also reported that pyrazole, an inhibitor 
of ADH, did not block the induced increase in rate of blood EtOH clearance 
seen in EtOH-treated animals. As stated before, alcohol tolerance does 
not appear to stem from increased ADH synthesis. However,Von Wartburg 
(1971) has described an atypical ADH in human liver. Atypical ADH has a 
different substrate specifities, different metal-binding characteristics, 
and different pH activity curves compared to typical ADH isoenzymes. 
However, the fall in plasma alcohol concentration in individuals with 
atypical ADH is only slightly increased .after acute EtOH drinking. 
The degree of importance of the MEOS, if it truly is a discrete 
enzyme, in the metabolism of EtOH and for the development of metabolic 
tolerance and cross-tolerance in alcoholics, remains to be determined. 
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Khanna et al (1970) have recently reported that contamination of in vitro 
systems by a "catalase-type " enzyme produced by cellular disruption, was 
responsible for the oxidation of EtOH by hepatic microsomal preparations. 
It is known that EtOH is a substrate for catalase, although methanol has 
four times the affinity for the enzyme. Most investigators still believe 
that ADH is the major enzyme responsible for the initial degradation of 
EtOH to AcD. 
However, the old idea that the ADH activity was the slowest and 
thus rate-limiting step in the degradation of EtOH has recently been 
challenged by Goldstein (1969). He points out that the Michaelis constant 
(Km) for the interaction of EtOH with ADH is about 2 x l0-2M. However, 
high blood alcohol concentration of 400 mg/100 ml. would be equivalent to 
8 x l0-2M., and moderate intoxication with blood EtOH levels of 100 mg/ 
100 ml. would yield values equivalent to 2 x 10-2M. It is therefore 
apparent that ADH is half-saturated at moderate blood levels. Goldstein 
suggests that the availability of hepatic NAD is a major factor in regula-
ting the zero-order kinetics of EtOH oxidation (that is, metabolism 
proceeding at a constant rate independent of the concentration of EtOH). 
This hypothesis is consistent with a number of studies that have clearly 
shown that in vivo metabolism of EtOH is associated with a significant 
decrease in hepatic NAD/NADH ratios. 
EtOH metabolism can be appreciably enhanced by administration of 
fructose (Carpenter and Leete, 1967). This knowledge has not been 
applied extensively clinically, although it has been postulated that 
intermediates of fructose metabolism affect the dissociation of the ADH-
NAD complex. 
The second major step in the degradation of EtOH involves the 
11 
conversion of AcD to acetate or acetyl coenzyme A. This reaction is 
catalyzed by ALDH and requires NAD as a cofactor (Racker, 1949). An 
NADPH-dependent aldehyde reductase, different from ADH, also exists in 
liver and brain. It can reduce AcD and aldehydes of biogenic amines. 
Low concentrations of barbiturates can inhibit aldehyde reductase, both 
in vivo and in vitro (Tabakoff and Erwin, 1970). 
It is well-known that the rate of oxidation of AcD is very rapid 
and exceeds the rate of oxidation of EtOH. Despite the short half-life 
of AcD, it has been shown that a number of unique effects of AcD cannot 
be produced by EtOH alone. For example, AcD has been shown to inhibit 
coenzyme A activity (Ammon ~ al, 1969) and pyruvate-stimulated oxidative 
phosphorylation in brain mitochondria (Truitt and Duritz, 1967). AcD 
appeared to compete with or bind to pyruvate in the later experiments. 
AcD may also affect the biotransformation and metabolism of catechol 
amines and biogenic amines by stimulating the release of NE from neural 
storage depots (Truitt and Duritz, 1966) and shifting the catabolism of 
NE and 5IIT from oxidative to reductive pathways (Walsh and Truitt, 1969). 
The mechanisms of action of ALDH are complicated to analyze since 
the enzyme seems to exist in multiple forms and in multiple areas of the 
cell. The enzyme was discovered by Racker (1949) in beef liver acetone 
powder extract. Dietrich (1966) found it to be highest in liver, and 
existing in most manunalian tissues including the brain, which is highest 
in ALDH in the caudate nucleus. Both mitochondria and cytosol contain 
the enzyme, with recent work pointing to the mitochondria as the more 
important during in vivo AcD (Marjanen~ 1972) metabolism. 
Several forms of ALDH seem to exist, Dietrich (1973) having found 
· by gel columns and isoelectric focusing two forms in mitochondria and the 
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following three forms in supernatant-- (1) phenobarbital-induced, (2) not 
phenobarbital-induced, disulfiram-resistant, oxidizing p-carboxybenz-
aldehyde but not propionaldehyde, and (3) having glycolaldehyde as a 
substrate. The enzyme or enzymes require NAD, optimally perform at pH 
9.6-10, denaturing irreversibly above pH 10, 'and oxidize benzaldehydes, 
aliphatic aldehydes, succinic semialdehyde, and aldehydes of endogenous 
amines (Erwin and Dietrich, 1966). AcD was found by the same workers to 
have two Km's, indicating either the existence of two enzymes or substra-
te activation, the latter mechanism having been reported by Duncan and 
Tipton (1971) for the substrates AcD and propionaldehyde. There may be 
NADP-dependent ALDH in mitochondria and microsomes, according to recent 
reports by Tottmar and Kiessling (1973). 
AIDH assays are usually done on tissue from male animals, largely 
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because steroids, which vary greatly in levels in females, can inhibit or 
stimulate the enzyme (Maxwell and Topper, 1961). Progesterone, testos-
terone and others inhibit ALDH independent of aldehyde concentration, 
while estrone, diethylstilbesterol and othe1S stimulate or inhibit the 
enzyme depending on substrate concentration. 
Induction of rat liver ALDH after injection of mice with pheno-
barbital for four days has been reported (Cohen and Redmond, 1971), 
probably due to the induction of the supernatant fraction of the enzyme. 
These workers postulated that cross-tolerance between EtOH and barbitu-
rates might exist if such an increase in AcD turnover occurred in animals 
or man. 
Several inhibitors of ALDH have been found, most of which have 
little structural similarity to each other. The pre-treatment of rabbits 
with 2-chloroacetophenone blocks ALDH in brain slices, as evidenced by 
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decreased formation of acids from labelled NE (Rutledge and Dietrich, 
1971). Sulfhydryl groups within the enzyme appear to be crucial, since 
administration of glutathione or various sulfhydryl reagents blocks the 
inhibition. A compound that inhibits ADH effectively, pyrazole, was 
found to have no effect on ALDH activity in tat liver or brain (Dietrich 
et al, 1971). However, aldehyde reductase was inhibited by pyrazole in 
the liver (but not in brain), the half-life of inhibition being 76 hours. 
Both disulfiram (tetraethylthiuramdisulfide, Antabuse) and its 
monomer, diethyldithiocarbamate (DDC), irreversibly decrease liver ALDH 
activity after their injection into the live animal (Dietrich and Erwin, 
1971). This inhibition seems to involve sulfhydryl groups of the enzyme. 
The return of activity appears to be dependent on protein synthesis, 
being blockable by cycloheximide. 
The severity of and unexplained human deaths from the disulfiram-
EtOH reaction ha\Bprompted a search for other drugs with a disulfiram-
(DS) like action that is sufficiently powerful to discourage drinking 
but does not endanger life. Ferguson (1956) has suggested citrated 
calcium carbimide, also called Temposil, as another drug in the treatment 
of alcoholism. Its effects and mode of action seem to be similar to 
those of DS, but its time relations are different. A sensitizing action 
to alcohol (flushing, palpitations, sweating, hypotension) is apparent 
within 30 minutes (instead of 5-10 minutes with DS), and it lasts for 
about 8-12 hours (rather than one-half to several hours after DS). 
However, it has been argued that lowered dosage of DS is all that is 
needed in most cases to remove the severe effects that are intolerable 
to or life-threatening for certain individuals (Fox, 1973). 
The hypoglycemic sulfonylureas may produce a reaction similar to 
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the DS-EtOH reaction and cause the AcD concentration of the blood to rise 
(Truitt and Duritz, 1972). 
At least two pharmacologically important compounds are kno\vn to 
inhibit both ALDH and ADH: the sedative chloral hydrate and the beta-
adrenergic blocker, propranolol. Chloral hydrate is reduced to trichlor-
ethanol, a substrate and competitive inhibitor of ADH and thus a poten-
tiator of EtOH intoxication, as in "Mickey Finn" knockout drops (Cooper 
and Friedman, 1958). The mechanism of ALDH inhibition by chloral 
hydrate remains to be elucidated. 
Propranolol is the widely used beta-blocker whose structure is 1-
(Isopropylamino) -3-(1-naphthyloxy)-2-propanol. According to Duncan(l973), 
the drug has been shown to inhibit several enzymes, including cholineste-
rase, monoamine oxidase, and the ca-H--induced activation of adenylate 
cyclase while it is able to increase the activity of tyrosine hydroxylase 
in rat striate cortex. Duncan (1973) has recently shown that the inhib-
ition of ADH by propranolol is competitive with respect to NAD+ but mixed 
with respect to EtOH, despite the hydroxyl group possessed by propranolol. 
Propranolol inhibition of pig brain ALDH is reversible and of the mixed 
type with respect to both NAD+ and aldehyde (3-methoxy-4-hydroxy-phenyl-
acetaldehyde). 
The kinetics of ALDH in pig brain have been described by Duncan 
and Tipton (1971). The enzyme binds its substrate and releases its prod-
ucts in a compulsory order: NAD+ is bound first, followed by aldehyde, 
and NADH is released after the acid product. The reaction is irreversi-
ble and is not inhibited by the acid products. High aldehyde concentra-
tions are inhibitory. Substrate activation by AcD or propionaldehyde, as 
seen with other manunalian ALDH enzymes (Erwin and Dietrich, 1966), was 
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seen by the authors, who postulated the existence of sub-unit inter-ac-
tion or of different enzymes with different Km and V values. 
In the present studies of ALDH, several compounds structurally 
similar to PG were tested for in vitro inhibition of ALDH. Of the various 
pyrogallol-related drugs tested for inhibitioµ of ALDH, only a limited 
arr~unt is known about the various actions and uses of these compounds. 
Pyrogallol inhibits catechol 0-methyl transferase (COMT), dehydro-
shikmate reductase, D-amino acid oxidase, and histidone decarboxylase 
(Webb, 1966). It can be prepared from gallic acid, and its antioxidant 
properties make it useful as a photographic developer and as an external 
antimicrobial and skin irritant (Merck). Propyl gallate is a very popular 
antioxidant for foods, fats, and oils (Merck). Hydroquinone is also a 
useful antioxidant and photographic developer (Merck). It is used occa-
sionally as a depigmentation agent in the treatment of hypermelanosis. 
This latter action may be due to inhibition of tyrosinase (Merck). D-amino 
acid oxidase is also inhibited by hydroquinone (Webb, 1966). The two 
methoxylated compounds, 3-methoxycatechol and 2,3-dimethoxyphenol, are 
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the products of 0-methylation of pyrogallol by COMT in vitro (Archer et al, 
1960). Shikimic acid (3,4,5-trihydroxy-cyclohexenoic acid), a non-aromatic 
compound with three vicinal hydroxyl groups, is an inhibitor of plan de-
hydroshikmate reductase (Webb). In plants, it is an important precursor 
in aromatic biosynthesis (Merck). RO 4-4602,an inhibitor of DOPA decar-
boxylase, has been used for the latter purpose to enhance L-DOPA levels 
in patients treated for Parkinsonism. Having the structure N - (DL-seryl)-
N2 -(2,3,4-trihydroxybenzyl) hydrazide, RO 4-4602 is basically a derivati-
ve of pyrogallol and seems to possess some of the same actions. Finally, 
1,2,4-trihydroxybenzene, 3,4-dihydroxy-tolvene, and tetrahydroxyquinone, 
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all have two or more hydroxyl groups on a benzene nucleus, and are thus 
structurally related to pyrogallol. 
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III. ETHANOL:NEUROCHEMISTRY 
More scientific light has been shed recently on the interrelation 
of alcohol, aldehydes, and biogenic amines. .In yjtro work by Majchrowicz 
(1972) points to enzyme inhibition by AcD as being the major factor in 
the effects of EtOH on amine metabolism. He"found that (1) the reductive 
shift was not necessarily caused by an increased NADH/NAD ratio, since 
addition of NAD did not affect the increase in formation of indole glycols; 
(2) monoamine oxidase (MAO) and catechol 0-methyltransferase (COMT) activ-
ity and NE uptake into synaptic vesicles are unaffected by EtOH 200 mM or 
AcD 25 mM, and finally (3) ALDH is inhibited by EtOH-derived AcD, and its 
decrease corresponds to decreased oxidation products of indole- and cate-
cholamines. In support of point 3, the aldehyde-amine metabolism data, 
is the work of Collins and Dietrich (1970). When EtOH, 100-400 mg/100 ml, 
was added to mouse tissue in vitro, a pyrazole-reversible 60% inhibition 
of liver ALDH was seen. The pyrazole effect suggests that AcD is res-
ponsible for the ALDH inhibition. Another newly-discovered enzyme, al-
dehyde reductase, which reconverts AcD to EtOH and is important in brain 
tissue, was increased 41% in mouse brain tissue following thirty days of 
EtOH-metrecal drinking. 
EtOH administration has produced contradictory results on neuro-
amine levels and on amine-biosynthetic enzyme activity as well as on pro-
tein synthesis in general. Acute EtOH administration d~'ressed brain 
protein synthesis in one study, while increasing synthesis when given for 
ten days (Von Korff, 1970 ). Tewari and Noble (1971),saw the reverse: 
decreased synthesis of brain protein and RNA following chronic ingestion 
of 10% EtOH. NE synthesis is also variably affected by EtOH administra-
tion in rats. Hoping that an increased NE synthesis would be seen in 
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order to explain alcohol tolerance, the opposite was seen by Friedhoff 
(1972). The activity of tyrosine hydroxylase, supposedly the rate-lim-
iting enzyme that converts tyrosine to dihydroxyphenylalanine (DOPA) en 
route to NE, was depressed in caudate nucleus after repeated alcohol 
injection. Acute administration caused no change, stated Friedhoff. 
EtOH is also known to be an.inhibitor of ion transport in nervous 
tissue (Israel, 1972), probably contributing to its role as an inhibitor 
of NE reuptake. EtOH at 0.1-0.25% depresses Na23 efflux (active trans-
port) without changing the action potential in rat brain cortex slices. 
However, both active transport and action potentials were inhibited in 
squid giant axons, although the active transport was more affected. 
EtOH appears to compete with potassium (IC'-) for a site on the Na+-K+-AT-
Pase enzyme; thus, the K+ concentration should be known in all experiments 
involving EtOH and ATPase. In the absence of added IC'-, the concentration 
of EtOH necessary to inhibit the ATPase by 50% is of the order of 0.2-
0.3%. This inhibition could be partly counteracted by increasing the 
concentration of IC'- in the medium. EtOH (1%) significantly (25%) inhib-
ited the active accumulation of radioactive NE by rat brain slices incub-
ated with 6 mM K+. EtOH (1%), however, did not affect the passive efflux 
of NE from preloaded brain slices nor its release when elicited by 
electrical stimulation, thus indicating that the action potentials are 
not inhibited. 
The theory of EtOH as a homeostatic regulator of amine levels 
has been advanced by Bacopoulous and co~orkers (1972). They have found 
an existing correlation between alcohol preference and brain neurotrans-
mitter level changes in CFl mice. Animals that "pursued" 2% alcohol 
solution in preference to water, had neuroamine levels resembling mice 
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that had been stressed by electroshock. Thus, increased 5HT and decreased 
NE levels were seen in stressed mice and in EtOH pursuers. EtOH apparently 
served to restore these "stress" levels to that of controls. That is, 
"the reinforcing properties of alcohol are attributed to its intrinsic 
stabilization of the labile neurotransmitter levels." As such, one may 
partly explain "addictive personalities" of animals and possibly humans 
in terms of inherited amine stability. 
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IV. CATECHOLAMINES=BIOSYNTHESIS AND METABOLISM 
The CAs, NE, E, and DA, are 3,4-dihydroxyl derivatives of phenyl-
ethylamine. They are widely distributed throughout the animal kingdom, 
most often in nerve cells. CAs are found in the peripheral sympathetic 
nervous system and in the adrenal medulla, and are unequally distributed 
in different areas of the central nervous system (CNS). Small amounts 
of CAs are also found in chromaffin cells scattered throughout the body. 
The subject of their pharmacology and biochemistry has ben reviewed by 
various authors (Axelrod,1971; Kopin,1969; Molinoff and Axelrod, 1971). 
NE is highly localized in peripheral postganglionic sympathetic 
nerves. Its concentration in some sympathetic ganglia maybe as high as 
100 microgram/gm, while in sympathetically innervated tissue its concen-
tration ranges from 0.1 to 0.2 microgram/gm. The nerve endings make up 
only a small pa.rt of the total mass of the tissue, and thus the actual 
concentration of NE in the endings is probably between 100 and 500 micro-
gram/ gm. Postga.nglionic stimulation leads to almost complete disappearance 
of NE from tissues, which suggests that it is wholly contained within 
the sympathetic nerves. In the CNS, the highest concentration of NE is 
found in the hypothalamus and brain stem. (Axelrod, 1971) 
NE is released from sympathetic nerve terminals as a neurotrans-
mitter and exerts most of its effect locally on post-synaptic cells. 
Epinephrine (E) functions mainly as a hormone, being released into the 
general circulation primarily from the adrenal medulla. Small amounts of 
E have been found in mannnalian brain and heart. A third CA, DA, serves 
as a precursor of NE and E in both the peripheral and central nervous 
systems. Its most important function may be in the brain, where high 
concentrations are found in the striatum. DA is thought to be a synaptic 
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transmitter functioning to mediate inhibition in a motor-coordinating ni-
gro-striatal pathway. Deficiency of DA in this area appears to be a . bio-
chemical correlate of Parkinson's disease. 
It has recently been possible to visualize CAs .in ~. A high-
ly specific and sensitive fluorescent histochemical method has permitted 
the direct visualization at a cellular level of the biogenic amines DA, 
NE, E, and 5HT. The'use of this technique has confirmed the conclusion 
that the NE present in peripheral mammalian tissue is localized almost 
exclusively in sympathetic nerves. More specifically, the use of gradient· 
centrifugation techniques, the autoradiographic localization of tritium-
labelled NE, and electron microscopy have combined to show that NE is 
localized not only within the sympathetic nerve endings, but also largely 
within specific vesicles contained in these nerve endings.(Axelrod, 1971) 
CAs influence the actions of a wide variety of tissues such as 
vascular smooth muscle, adipose tissue, liver, heart, and brain. In many 
cases they act by causing an increase in the activity of a specific en-
zyme or enzymes. These effects are frequently mediated by adenosine 3 1 , 
5'- monophosphate (cyclic AMP). 
The biosynthesis of CAs begins with tyrosine. The four enzymes 
involved _in CA ~iosynthesis -- tyrosine hydroxylase (TH), DOPA decar-
boxylase (DOPA-D}:lopamine B-hydroxylase (DBH), and phenylethanolamine N-
methyltransferase (PNMT) -- do not have the same subcellular distribution. 
Thus, intracellular migration of substrates for these enzymes takes place 
as tyrosine is converted to NE in the sympathetic nerves and to E in the 
adrenal medulla. 
Although the pathway of tyrosine to DOPA to DA to NE to E is the 
major pathway of CA biosynthesis, lack of specificity of several enzymes 
involved permits several alternate pathways. One such pathway from 
tyrosine to NE and E may exist via tyrosine, tyramine, octopamine and 
synephrine. There is also a pathway from tyrosine to E which bypasses 
NE. In this reaction sequence, DA is converted to epinine by a non-
specific phenyalkalamine N-methyltransferase which has been found in 
rabbit lung. Epinine can then be beta-hydroxylated by DBH to form E. 
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Although CAs are rapidly inactivated when they enter the blood-
stream, they are stored in high concentration in the adrenal medulla, 
sympathetic neurons, and certain areas of the brain. In the adrenal 
medulla they are held in granules that contain high concentrations of ATP 
in a CA/ATP ratio of 4:1; DBH; a group of nine specific proteins called 
chromggranins, having a molecular weight of about 77,000; and an ATPase 
dependent on Mg+t and Ca+t. These granules can take up radioactive E 
from solution by an energy-dependent process inhibited by drugs such as 
reserpine. On the basis of these observations, it is believed that the 
CAs in the granules are bound in a protein-ATP complex that may involve 
a divalent anion. 
In the sympathetic nerve endings, NE is similarly found in the 
particulate fraction that contains dense-core vesicles. Only those 
amines that are bound in vesicles are released by nerve stimulation; and 
if binding in vesicles is prevented, even NE present in the soluble frac-
tion is not released. Drugs such as reserpine, which deplete NE, cause 
disappearance of the dense-core vesicles. NE and E appear to be stored 
in two different granule types in the adrenal medulla. 
The chemical structures relevant to binding have also been 
studied. NE has a catechol group, a beta-hydroxyl group, and an amine 
group. To determine which chemical structures may be involved in the 
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binding mechanism, related compounds that lack one or more of these 
groups have been studied. The amine group is necessary for binding. 
Phenylethylamine, which has only the amine group but none of the hydroxyl 
groups, is not bound; but phenylethanolamine can be bound by the vesicles 
to a slight extent. The beta-hydroxyl group, therefore, appears to con-
tribute to binding. DA, which lacks only the beta-hydroxyl group of NE, 
is relatively strongly bound to the vesicles; thus, the catechol group 
appears to be involved in the binding mechanism. When either of the 
catechol hydroxyl groups of NE is lacking, as in m-octopamine or p-octo-
pamine, the avidity for binding sites appears to be diminished in vivo 
as well as in vitro. This incomplete specificity of binding allows re-
placement of NE by other amines, so-called "false transmitters." Accu-
mulation of false transmitters in vesicles diminishes the amount of NE 
that is released, thereby causing a partial adrenergic blockade when less 
active NE reaches the receptor site. (Molinoff and Axelrod, 1971). 
Endogenous amines apparently are released by nerve stimulation 
only if they are bo4nd in vesicles. However, mechanisms for releasing a 
compound from nerv~ endings that do not involve vesicle binding may also 
be present. Bretylium is a quaternary amine that interferes with the 
release of NE from the sympathetic nerves. Although not bound in vesicles, 
bretyli:um accumulates in sympathetic nervous tissue and is released 
during nerve stimulation. It is thus apparent that a substance need not 
be bound in vesicles in order to be released. 
NE that is released at the adren:ergi.c nerve ending reaches an 
effector cell where it reacts with a specific site, the receptor, to 
initiate a sequence of evehts that leads to a response. Adrenergic re-
ceptors have been separated into two main types, alpha and beta, based 
24 
on the structure-activity relation of various compounds (agonists) that 
intereact with the receptor. The order of potency at the alpha receptor 
(e.g. vasoconstriction) is NE > E > isoproterenol. At beta receptors 
(e.g. vasodilatation or myocardial chronotropicity) this order is revers-
ed (Kopin, 1969). 
Further, the notion that there are two main types has been great-
ly strengthened by the discovery of drugs that specifically block one but 
not the other type of receptor (Kopin, 1969). 
In addition to responses that involve muscular contraction or 
glandular secretion, CAs have several metabolic effects (e.g. hyperglyce-
mia). The mechanism of a number of these effects has been shown to be 
increased formation of cyclic AMP from ATP as a consequence of activation 
of adenyl cyclase. There is some evidence that the beta receptor is 
pharmacologically similar to the site of interaction that results in 
activation of adenyl cyclase (Kopin, 1969). 
After release, rapid inactivation of CAs occurs, primarily (80%) 
due to uptake into the presynaptic nerve endings. The neuronal uptake 
mechanism obeys saturation kinetics of the Michaelis-Menten type, re-
quires energy derived from glycolysis or oxidation, is stereospecific 
for the L-isomer of NE, and requires the sodium ion. Many other amines 
can be taken up and stored in sympathetic nerves by a neuronal uptake 
process. These amines include tyramine, alpha-methyl NE, metaraminol, E, 
and DA. Cocaine and antidepressant drugs such as imipramine and sympa-
thomimetic amines (amphetamines) block the uptake of NE in the nerve. 
Compounds that block uptake also prevent the inactivation of NE and thus 
prolong its physiologic actions (Molinoff and Axelrod, 1971) . 
• 
An extraneuronal uptake process for NE, called uptake 2, has been 
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found which is blocked by normetanephrine (a metabolite of NE) and by 
adrenergic blocking agents like phenoxybeuzamine. Uptake 2 operates at 
all concentrations of CAs to transport the amines into nonneuronal tissues 
where they are subsequently metabolized. Compounds such as E and iso-
proterenol which have a relatively low affinity for intraneuronal uptake 
and a high affinity for Uptake 2 may be inactivated mainly by the latter 
process (Axelrod, 1971). 
According to Molino££ and Axelrod (1971), the main CA catabolic 
enzymes are catechol 0-methyl-transferase (COMT) and monoamine oxidase 
~1AO). These enzymes act on CAs to produce physiologically inactive 
metabolic products, but neither of these enzymes plays an enormous role 
in terminating the physiological action of the neurotransmitter NE or of 
the hormone E. The rapid inactivation of CAs is due to reuptake into 
presynaptic endings. It has been estimated that 80% of NE released in 
sympathetic nerve endings is inactivated by reuptake, with 20% being 
catabolized by enzymes. COMT appears to be more important than MAO in 
metabolizing E and NE in the rat. In addition to these two major enzymes 
of CA metabolism, two other enzymes -- aldehyde dehydrogenase and alde-
hyde reductase -- are present and act on the products of MAO and COMT 
actions. In humans, vanillylmandelic acid (VMA), the product of COMT, 
MAO and aldehyde dehydrogenase action on NE and E, makes up about 40% of 
the total urinary CA metabolites. The primary metabolite of NE from 
brain is 3-methoxy-4-hydroxy-phenylglycol, formed via COMT, MAO, and 
aldehyde reductase. About one-third of the total CA metabolites in human 
urine comes from DA (Molinoff and Axelrod, 1971). 
f 
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The search for CA 0-methylating enzyme was prompted by the 
observation that NE and E are metabolized to the corresponding 3-0-
methylamines, normetanephrine and metanephrine, respectively. COMT, 
first described in rat liver, requires S-adenosylmethionine (SAM) as a 
methyl donor. SAM is synthesized throughout the body from methionine 
and ATP. COMT requires divalent cations such as Mg-++ for activity, 
but other ions can substitute, including manganese, cobalt, zinc, iron, 
cadmium, and nickel. 
Rock et al (1970) compared the properties of rat brain COMT 
with that of liver. The two enzymes have similar pH optima, heat stabil-
ities, molecular weights, and responses to inhibitors. However, brain 
COMT was found to have one less activity band (by electrophoresis) and 
one-tenth the specific activity of the liver enzyme. The optimum activ-
ity of COMT from either organ was obtained at pH8, using 0.01 M Mg-++. 
The substrates for COMT include NE, E, DA, DOPA, 3, 4-dihydroxy-
mandelic acid, 3, 4-dihydroxyphenylacetic acid, 3-hydroxyestradiol, and 
ascorbic acid. The latter can be 0-methylated on the alpha-carbon after 
forming a cyclic ether. The enzyme can also 0-methylate exogenously 
administered catechols such as 3,4-dihydroxyephedrine, 3,4-dihydroxy-
. 
amphetamine, and a variety of substituted catechols and polyphenols but 
not monophenols (Axelrod, 1968). 
In vivo, 0-methylation occurs mainly on the meta position. Poly-
phenols with non-polar side-chains such as acetophenones, however, may 
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have up to 50% para 0-methylation. A novel type of interconversion of 
4-methoxy-3-hydroxy-acetophenone to 3-methoxy-4-hydroxy-acetophenone 
occurs in vivo. This results from the 0-demethylation of the 4-methoxyl 
compound to form a catechol which is subsequently 0-methylated on the 
3-position by COMT, according to Creveling ~al (1970), finding 
that COMT has a molecular weight of approximately 24,000. At least 
two separate forms have been identified on starch-block electrophoresis. 
The enzyme can be inhibited by dichloromercuribenzoate, which 
suggests that the enzyme has a sulfhydryl group in the region of its ac-
tive site. Chelating agents such as tropolone can inhibit COMT. A 
normally occurring catechol compound that blocks 0-methylation in vitro 
and in vivo is 3-hydroxyestradiol. Other competitive inhibitors are 
dihydroxyphenylacetamide, pyridoxal phosphate, and polyphenols such as 
pyrogallol (l,2,3~trihydroxybenzene). Another group of COMT inhibitors 
are substituted 3,5-dihydroxy-4-methoxybenzoic acids, which act non-
competitively and are effective in vivo. (Nikodejevic ~al, 1970) 
The inhibition of COMT by pyrogallol (PG) is of interest because 
of the bearing it has on the metabolism of E and NE. Bacq (1936) observ-
ed that PG increased the responses of tissues to sympathetic nerve stim-
ulation and to E. However, he then attributed this action to the anti-
oxidant properties of PG. The inhibition of COMT was reported by Bacq 
who believed that this could explain the sensitivity of smooth muscle to 
the CAs by PG and other phenolic compounds. The half-life of NE in mice 
is increased from 22 to 42 minutes by 10 mg PG, (Webb,~ 1966), while 
0-methylation is inhibited 99%, indicating other pathways for NE metab-
olism. Probably the MAO pathway is also important. The administration 
of PG to rats does not by itself increase brain NE levels, but it does 
in conjunction with iproniazid (MAO inhibitor),since the two major NE 
degradation pathways are blocked (Jaattela and Paasonen, 1961). 
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Repeated administration of PG causes a rise in blood pressure, 
but this is soon followeiby a loss of response or tachyphylaxis. The 
rate of urinary excretion of 0-methylated derivatives of the CAs is 
briefly decrease by PG, but if the administration is continued, the rate 
returns to normal. Long-term tr.eatment with PG leads to an increase in 
COMT and MAO activity in the liver of rats, so it may well be that these 
enzymes are adaptively altered. Excretion of 0-methylated products of 
CAs reach a minimum at five days, returning to normal in twenty-five 
days. Urinary CAs,on the other hand, increase for twenty days, then 
slowly return to their pre-PG levels, despite continued PG injections 
(Wylie et al, 1960) 
The kinetics of in vivo inhibition of COMT have been studied by Crout 
(1960). Inhibition occurs very rapidly in liver, heart and brain even 
when the PG is injected i.p., and by 30 minutes has developed appreciably. 
PG inhibition lasts 30-60 minutes with a single dose of 200 mg/kg, but 
last for several hours after injections of 50 mg/kg every 30 minutes for 
several hours before in vitro assay, measuring NE conversion to normeta-
nephrine. The inhibition by PG is only partly competitive (actually the 
curves appear to indicate noncompetitive inhibition) despite the fact 
that PG is a substrate for the enzyme (Archer, 1960). The Ki of 0.008 mM 
for PG indicates the high potency of the inhibition (Km for NE is 0.3 mM). 
The only other animal enzymes reported to be inhibited by PG are D-amino 
acid oxidase, dehydroshikimate reductase, and histidine decarboxylase 
(Webb, 1966). 
COMT is localized in highest concentrations in the liver and 
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kidney in most animals. There is an unequal distribution of COMT in the 
brain, activity being highest in the area postrema and lowest in the 
cerebral cortex. Although most of the enzyme is found in the soluble 
fraction of the mammalian cell, there are also small amounts present in 
fat-cell membranes, erythrocyte membranes, ahd in microsomes. In sym-
pathetic tissue, COMT is present mainly outside the neuron, in contrast 
to MAO which is present intraneutonally. 
Recently the so-called peripheral beta-adrenergic receptor has 
been suggested to be a membrane catechol-binding protein which may be 
related to COMI' (Cuatrecasas et al, 1974). Some well-known COMT inhib-
itors (tropolone, pyrogallol, and 3,4-dimethoxy-5-hydroxy-benzoic acid) 
which do not have beta-adrenergic activity could inhibit the binding of 
NE to liver microsomes, the.significance of which is controversial. 
Physiologically, COM!' is involved in the metabolism of CAs 
released into the circulation and in the inactivation of NE in tissues 
lacking an abundant adrenergic innervation. COMT may also be associated 
with an extraneuronal uptake mechanism (Uptake 2). 
Thus, the current concept of the adrenergic nerve has been 
described. The cell body manufactures vesicles and various synthetic 
enzymes which are transported by axoplasmic flow to the nerve terminal. 
Fast flow along the neurotubules carries the enzyme DBH, which converts 
DA to NE. The DA is derived from tyrosine which passes into the axon 
and is acted upon by synthetic enzymes. When stimulated by calcium, the 
vesicle passes along a contractile neurofilament to fuse with the cell 
membrane and' extrude the contents of the vesicle, including proteins, 
DBH, ATP and NE. After the "exocytosis," the vesicle reaggregates as a 
smaller granule. Release can be increased by reserpine, tyramine, and 
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amphetamine. The released NE can enter into any of four processes: (1) 
NE can activate the receptor on the effector organ, this activation 
being diminished when structurally similar "false transmitters" replace 
some of the NE in the vesicles; (2) NE can pass into the circulation, 
where other tissues will probably inactivate it; (3) NE can be taken up 
by the neuron (Uptake 1) into presynaptic vesicles, and may be oxidized 
by MAO before vesiculization, thus having to pass out of the cell into 
the circulation; (4) NE can be taken up by other cells (Uptake 2), where 
COMT and possibly MAO catabolize NE, the products of which will then be 
excreted, probably as a glucuronide conjugation product of the liver. 
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V. ETHANOL AND AMINE-DERIVED ALKALOIDS 
Scientific interest in aldehyde-plus-amine-derived isoquinolines 
in alcoholism was stimulated in the 1960's by a fluorescence method for 
the visualization of CAs in tissues which is based on formation of iso-
quinolines. When freeze-dried tissue slices' are exposed to moist formal-
dehyde vapor at 80°c., the aldehyde and the endogenous CAs undergo a 
Pictet-Spengler (1911) type of condensation via a Schiff base (imine) 
intermediate to yield TIQ alkaloids. Subsequently, these alkaloids are 
oxidized to 3 ,4-dihydrois'oquinolines which tautomerize to fluorescent 
quinone imines (Corrodi and Hillarp, 1964). 
Collins and Cohen (1968),Robbins (1968), and others recognized 
the structural similarities between these products and plant isoquinoline 
alkaloids. Robbins stated the po~sibility that trace amounts of TIQs 
may form from AcD in vivo and have a relationship to alcohol addiction. 
He also added that "pharmacologically significant formation of these 
alkaloids might occur enzymatically, intracellularly or at sites of 
localized, high concentrations of the reactants." Possibly, they would 
act as sympathomimetics during alcohol withdrawal, creating a need for a 
depressant such as alcohol to restore physiological normalcy. Collins 
and Cohen reported the preliminary results of bovine adrenal perfusions 
with AcD, in which simple TIQs derived from NE and E were detected. 
Following this, several reports emerged of CA-derived TIQ form-
ation in animals. In vitro, TIQs were formed in cow adrenals after 
perfusion with AcD. (100 fg/ml) also cr~ated TIQs through adrenal per-
fusion (Cohen, 1971). Similar results in vivo were seen in rat adrenals 
after intraperitoneal injections of methanol, using detection by fluores-
cence microscopy (Cohen and Barrett, 1969), or by thin-layer chromate-
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graphy (Collins and Cohen, 1970). 
These studies were involved primarily with the CAs, norepinephrine 
(NE) and epinephrine (E), while Davis and co-workers (1970) probed the 
condensation reactions involving the CA, dopamine (DA), the inunediate NE 
precursor localized chiefly in the caudate n~cleus of the marrnnalian brain. 
Rather than examine only the AcD-DA condensation product, "sal-
solinol," Davis~ al studied the formation of a possible morphine pre-
cursor, tetrahydropapaveroline (THP), from the condensation of DA with 
the aldehyde metabolite of DA. DA is known to be enzymatically oxidized 
in vivo by monoamine oxidase to 3,4-dihydroxyphenylacetaldehyde (DA-Ald). 
-- ---~ . 
This unstable product is quickly oxidized by aldehyde dehydrogenase (ALDH~ 
and a. competitive inhibition of ALDH would occur, thus raising the 
levels of DA-Ald. This increased DA-Ald could then condense with the 
parent amine, DA, creating the larger molecule THP. EtOH-evoked diver-
sion of DA biotransformation to this benzyltetrahydroisoquinoline 
alkaloid could be related to the dependence-producing properties of 
alcohol, argued Davis. That THP provides the starting point for the 
elaboration of the complete morphine skeleton by the opium poppy has been 
supported by tracer experiments (Leete, 1959). The possibility was 
suggested that animal systems could also mediate this specific reaction 
sequence. Davis makes the controversial case that many opium addicts 
revert to alcohol and vice versa, because the biochemical mechanisms of 
a~cohol and opiate addiction are both opiate-based. It is known, howev-
er, that rats susceptible to morphine addiction can also be addicted to 
alcohol with greater ease than those which do not prefer morphine-contain-
ing water (Davis et~. 1970). 
Davis et al (1970} did find that the formation of the alkaloid 
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THP in rat brain homogenate occurred to a greater degree following the 
addition of EtOH or AcD. This effect was apparently due to inhibition of 
ALDH, leading to decreased formation of 3,4-dihydroxyphenylacetic acid 
from DA-Ald. Further, the effect on THP formation of the cofactor nico-
tinamide adenine dinucleotide (NAD) was seen. Enhanced THP formation was 
seen, apparently as a result of greater acetaldehyde inhibition of the 
oxidation of DA-Ald. Another reason cited was the decreased formation of 
salsolinol, due to rapid AcD oxidation, thus allowing a significant in-
crease in the amount of DA available for reaction with its intermediate 
aldehyde to form THP. 
In the category of putative neurotransmitters in animals, the CAs 
are joined by histamine, acetylcholine, serotonin (5-HT), and others. It 
is likely that many of these are affected by EtOH or AcD. Interestingly, 
the idea of AcD condensation products from 5HT-like amines has been ad-
vanced by Mclsaacs since 1961. He reported the presence of a 1,2,3,4-
tetrahydro-beta-carboline alkaloid in the urine of rats treated with EtOH, 
5-methoxytryptamine, iproniazid (a monoamine oxidase inhibitor), and 
disulfiram (an ALDH inhibitor). Various beta-carbolines can be synthe-
sized, e.g. from 5HT plus AcD, analogous to TIQ formation from CAs. 
6-methoxy-1,2,3,4-tetrahydro-beta carboline is a brain serotonin elevator 
in mice, possibly acting as an inhibitor of 5HT synthesis (Mcisaacs~t al, 
1972). Thus, isoquinolines and beta-carbolines may form after alcohol 
ingestion. They may act by altering neuroamine levels or by direct effect 
upon receptor sites. 
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VI. METABOLISM AND PHARMACOLOGY OF BIOGENIC AMINE-DERIVED ALKALOIDS 
The various alkaloid theories of alcoholism have been mentioned: 
(1) CAs combining with simple alkaloids to form TIQs; (2) DA combining 
with its aldehyde metabolite to create THP; and (3) serotonin derivatives 
combining with simple aldehydes to yield beta-carbolines. All of the 
concepts revolve around the idea that plant-like alkaloids may form in 
animals after alcohol ingestion. The properties of these alkaloids pos-
sibly create some of the physiology of alcohol toxicity and withdrawal 
symptoms. Therefore, interest in isolating these compounds and their 
metabolites in animal tissues has increased in recent years. 
Metabolites of alkaloids in plants are reviewed in great detail 
by Reti (1954). 0- and N-methylation are the principal processes involv-
ed in the interconversion of TIQ alkaloids, for example. Many of the 
products of these reactions are more toxic in certain ways than are 
their precursors. Demethylation also occurs, as in the conversion of 
salsoline to salsolinol in desert cacti. 
Many metabolic pathways followed by plant alkaloids are active in 
animal tissue as well. Numerous 0- and N-methylating enzymes, as pre-
viously described, methylate numerous endogenous amines. Catechol 0-
methyltransferase is widespread, inactivating CAs; guiacol 0-methyltrans-
ferase is reported to add a second methoxy group to 0-methylated DA prod-
ucts (Friedhoff et al, 1971); phenylethanolamine N-methyl-transferase 
will N-methylate NE and other compounds (Axelrod, 1962); a nonspecific 
N-methyltransferase in rabbit lung can act on 5HT, tryptamine, tyramine 
and the CAs (Axelrod,1961); histamine N-methyltransferase, hydroxyindole 
0-methyltransferase, demethylases, and water methylases also exist 
(Axelrod 1962). 
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Mixed-function liver oxidases are also known to form N-oxides of 
hydrazines and of various arylamines such as morphine, nicotine, chlor-
promazine, and amphetamine. The nitroso products can be reconverted to 
their precursor using cytochrome reductase. The regulatory site can 
be activated by amphetamine or various phenylethylamines. Modifiers of 
the oxidases include barbiturates, which increase oxidative demethylase 
activity, and amphetamines, activators of N-oxidase in human and pig 
liver. N-oxides of heterocyclic compounds such as T!Qs are seen in plants 
(Ziegler, 1972). 
The mechanisms of actions of TIQ alkaloids in animals have been 
investigated. They easily foltn.in vitro in adrenal tissue, as stated. 
Other areas where these alkaloids might form are in the adrenergic fibers 
of the sympathetic nervous system and brain. These alkaloids retain the 
original CA structure, but ring closure prevents rotation of the ethanol-
amine side chain. If the resultant conformational site were to corres-
pond to that required for binding to smooth muscle or brain receptor 
sites, these substances could be unique neurotransmitter or blocking 
agents. They appear to be bound to adrenal, brain and nerve tissue, 
possibly at the same loci as CAs. Cohen and Collins (1970) suggested 
that TIQs alkaloids, either actively secreted or leaked from nerve term-
inals, could contribute to the behavioral changes.caused by alcohol. A 
portion of the characteristic neurologic disturbances, such as hyper-
excitability, tremulousness, hallucinosis, and seizures, which occur 
when blood concentrations of alcohol are falling or absent, could be due 
to the persistent physiologic action of the TIQ alkaloids. 
The TIQ alkaloids derived from the CAs are structurally similar 
to a number of naturally occurring alkaloids, such as anhalamine, salso-
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line, and carnegine, which are found in desert cacti, (Reti, 1954) and 
which exhibit pharmacologic actions such as excitation, narcosis, blood 
pressure changesand convulsions. Five to ten milligrams of pellotine, 
an anhalamine derivative, can cause convulsions in a frog. The most 
toxic of this group, lophophorine, tetanizes a frog at levels of 250 
micrograms. But dose-dependent qualities exist, especially so at the 
12.5 milligram level, above which blood pressure drops in intravenously 
injected rabbits, while higher pressure occurs below 12.5 milligrams. 
According to Schultes, (1969) the TIQ alkaloids found in peyote 
are hallucinogenic and are responsible for the differences between the 
intoxication state produced by peyote versus that produced by pure 
mescaline, the major active ingredient. The reported pharmacological 
properties of TIQ derivatives of CAs include inhibition of uptake and 
storage of CAs in nerve and brain. Cohen (1973) demonstrated that 6,7-
dihydroxy-TIQ (DA-derived) is accumulated by rat iris, sympathetic nerve 
endings, and brain synaptosomes. This TIQ was shown to block NE and DA 
uptake in brain synaptosomes. Intraventricular injection of this TIQ 
caused a dose-related decrease in the body temperature of rats, shown to 
be related to the release of CAs. Thus a DA-derived TIQ, as well as 
other related alkaloids (Alpers et al, 1974), possess properties that 
would serve to prolong or enhance the physiological effects of the CAs. 
Biosynthesized TIQs may then function as false adrenergic transmitters. 
Direct pharmacological effects of CA- related TIQs have been 
shown. The complex benzylisoquinoline derivative of DA, tetrahydro-
papaveroline (THP), is reported to act as a direct beta-sympathomimetic 
agent (Santi et al, 1972). The EEG stimulant effect of condensation 
products of AcD with mescaline, spermidine, tryptamine, gl~tamine, and 
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histidine, is greater for the condensation product than for the parent 
amine (Beck et al, 1968). Similarly, it has been seen that - the 
reversal of pentobarbital sedation occurs to a larger extent with the 
TIQs than with NE (Goldstein, 1970). 
Of possible significance is the report by Heath (1965) that 
schizophrenics under aldehyde-elevating disulf iram therapy are noticed 
to undergo a worsening of their mental condition. This response might 
in part be due to the stimulant effect of condensation products formed 
from endogenous amines with the increased aldehydes. Of course, other 
toxic effects of disulfiram may be active in this case as well.. In a 
survey of pharmacologic actions of synthetic, phenolic TIQs, all lacking 
the 4-hydroxyl group of NE-derived TIQs, Hjort et al (1938) observed 
effects on blood pressure, respiration, and smooth muscle, as well as 
anti-anesthetic properties, blockade of pressor responses to epinephrine, 
tremor, and convulsions. Recently, L. Goldstein (1970) found a mescaline-
like reversal of pentobarbital sedation following injection of a 6,7-
dimethoxy-TIQ in rabbits. The pharmacology of the 4-hydroxy..lfIQ alkaloids 
used in the· experiments in this dissertation research has not yet been 
studied. 
A. Collins et.al (1973) recently reported the 0-methylation in 
rat brain and liver of both salsolinol, a DA-AcD condensation product, 
and of THP, a DA-derived benzylisoquinoline. Salsolinol was a better 
substrate in vitro for COMT than was its parent amine, DA. Salsolinol 
also served as a moderate competitive inhibitor of both COMT and MAO, 
although no specific metabolite of these alkakids was detected after 
incubation with MAO. It is not known whether MAO can break the hetero-
cyclic ring of the TIQs in order to achieve possible deamination. THP 
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was found by these workers to form two 0-methylated products, while 
salsolinol yielded only one. 0-methylation in vivo and in vitro via COMT 
also was reported for trimetoquinol (Meshi, 1970), another benzylisoqui-
noline related to THP. Similarly, N-methylation has been reported for 
harmaline, a compound that has a beta-carboline structure and MAO inhib-
itory activity (Ho et al, 1971). However, the metabolism of beta-hydroxy-
TIQs, such as those derived from NE, has not been studied prior to this 
work. 
Thus, much of alkaloid metabolism in animals is similar to that 
in plants. And further, CA-derived TIQ alkaloids seem in the limited 
studies done thus far, to be handled through the same metabolic pathways 
as their parent CAs. 
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VII. ANIMAL MODELS FOR ALCOHOLISM 
Since the demonstration by Isbell et al (1955) that the alcohol 
withdrawal syndrome can be induced in man under controlled laboratory 
conditions, progress in the research of EtOH dependence has been slowed 
by the lack of suitable animal models. Richter (1956) has never observ-
ed overt alcohol intoxication with withdrawal symptoms in laboratory 
rats. He found intoxication in only three of thirty wild Norway rats 
drinking aqueous EtOH solutions as the only liquid. Rats have a tendency 
to avoid such solutions entirely, or drink only at night, becoming sober 
by sun-up. More recently, convulsions and "hallucinatory behavior" were 
induced in five dogs following withdrawal of alcohol administration 
through surgically implanted gastric cannulae (Essig and Lam, 1968). 
The evaluation of this animal model is difficult because the dogs devel-
oped gastrointestinal ulcerations and possible hypoglycemia, due to 
absent or markedly diminished food intake during the withdrawal period. 
Ellis and Pick (1971) have also developed an alcohol intubation 
technique that can produce human-like withdrawal symptoms in monkeys and 
dogs, after three and six weeks of EtOH ingestion, respectively. The 
mean daily dose of EtOH is increased from 2 g/kg to 5-6 g/kg, an amount 
that is approximately equal to two pints of 100-proof distilled beverage 
consumed daily by a human subject weighing 150 pounds. The blood EtOH 
generally fluctuates between 100 and 500 mg/100 ml. Withdrawal symptoms 
were classified into the following stages of progressive severity: (1) 
tremulous, (2) spastic, and (3) convulsive. Death may or may not follow 
stage 3 in untreated animals. Administration of EtOH or barbiturates in 
these animals will entirely interrupt the withdrawal reactions at any 
stage. 
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For reasons of economy, however, most investigators prefer to 
use smaller animals, specifically rodents, in their search for an animal 
model for alcoholism. In the past, the two reasons cited for the inabil-
ity to induce alcohol withdrawal reactions in laboratory rodents by the 
forced drinking of aqueous EtOH solutions were: (1) The total amount of 
EtOH which can be administered orally in aqueous solution is too small, 
and (2) the EtOH is consumed predominately during the night, leaving the 
daytime for recovery. Preliminary experiments by Freund (1969) with 
10-25% aqueous EtOH solutions as the only drinking fluid demonstrated 
that mice consumed only up to 22% of calories in the form of EtOH and 
drank only during the night. Liquid diets of an EtOH-Metrecal mixture as 
the sole food were lethal within two weeks in Freund's lab when 45% or 
.more of calories were supplied in the form of EtOH. Feeding of liquid 
diets containing 35% of EtOH-derived calories resulted in nearly even 
distribution of fluid intake between the day and night hours and were 
well tolerated. Freund has described an animal model that used initial 
30% weight reduction of mice followed by forced choice presentation of 
liquid diets containing EtOH 6% of volume, or 35% of total calories. 
Apparently, weight reduction decreased the rate of EtOH degradation in 
these animals. 
Freund claims to have induced seizure disorders, and later learn-
ing deficits, after abrupt replacement of alcohol by isocaloric sucrose 
in the basic liquid diet. Withdrawal was begun after the mice had been 
moderately to severely intoxicated in at least two-thirds of the daily 
ratings for four to five days. Light intoxication was defined as ataxic 
but rapid gait; severe as coma with::>ut righting reflexes; and moderate 
as in between light and severe. After substituting isocaloric amounts of 
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sucrose for EtOH, four stages of withdrawal were noted: (1) overactivity, 
sq~ing, generalized tremors 1-5 seconds in duration; (2) stage 1 plus 
rapid tail-beating; forward arching of the tail over the back to the nose 
(so-called Straub tail); slow-broad-based gait and retropulsion; repeti-
tive movements; (3) generalized tonic-clonic convulsions of 6-20 seconds' 
duration; (4) death during convulsion, or the animal may recover gradual-
ly, exhibiting the signs of Stage 2 for 8-24 hours while crouched against 
the cage wall with eyes open. Freund reported that 7 of 10 of these ICR-
DUB mice reached the convulsive stage. Freund ruled out hypoglycemia, 
starvation ketosis, and Metrecal diet as sources of convulsions. In 
later experiments, he replaced previous weight reduction with cold-room 
environments, (Freund, 1973 ), thus stimulating greater drinking by the 
mice. 
One critic of Freund's animal model, Mendelson (1971), believes 
that malnutrition may in part be responsible for the withdrawal symptoms 
seen. He states that the Freund diet did not make it clear if the mice, 
while on 1-12 weeks of alcohol diet, had regained their basal pre-alcohol 
administration weight. 
The frequency of malnutrition in human alcoholics, is, in part, 
associated with social and environmental conditions, states Mendelson. 
It is possible that vitamin deficiencies, which are believed to be of 
great import in alcohol-related neuropathologies, have been reduced 
because of greater availability of vitamin-enriched foods. 
The poor dietary intake by alcoholics when they are drinking 
cannot be totally attributable to the fact that alcohol, which contains 
7 calories/gm, suppresses appetite or replaces a need for other caloric 
intake. Recent studies by Mendelson (1970) and co-workers indicate that 
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alcoholics may consciously refrain from eating because they wish to 
obtain a better or greater response from a given dose of alcohol. The 
mechanism underlying this phenomenon is related to a decreased rate of 
EtOH metabolism that occurs as a consequence of food deprivation or 
starvation. Thus, alcoholics learn that enhanced inebriation can be 
obtained through decreased food intake during a drinking episode. To a 
lesser extent, the suppression of appetite due to EtOH also plays a 
role in food abstinence. Mendelson postulated that brain damage in 
alcoholics results from a combination of factors -- neuropathophysiolo-
gical effects of direct EtOH toxicity, food deprivation, and alcohol 
withdrawal states -- rather than from a single cause (Mendelson, 1970). 
One recent alcohol dependence experiment in the rat involves 
gastric intubation. Wallgren et al (1973) used tert-butanol, primarily 
-- --
because it is not oxidized, thus avoiding the complication of its actions 
by aldehydes. The tert-butanol was given to rats twice daily for 21 
days along with a liquid diet, the latter to avoid constipation. A state 
resembling a severe withdrawal illness was observed when the tert-butanol 
was stopped. Thus, EtOH-like withdrawal symptoms can result after 
administration of alcohols other than EtOH. 
Mello and Mendelson (1973) maintained monkeys in a reward-
association paradigm in which a drinking response yielded a dry food 
pellet. The delivery of the pellets is accompanied by consumption of 
large quantities of fluid. However, neither marked intoxication nor ev-
idence of withdrawal signs were seen d~ring six-monthsof daily 3-hour 
polydipsia sessions. 
PART.TWO 
EXPERIMENTAL 
A. MATERIALS 
Acetaldehyde-Eastman, redistilled into small vials when needed 
and stored at - 20°c. 
3 1 5 1 - adenosine triphosphate 
Sigma. 
disodium salt, equine muscle -
Adsorbosil-1 TLC powder - Applied Science Labs. 
Aluminum oxide - Grade I Neutral - Woelm. activated by ·HCl 
Ascorbic acid - Lilly 
BBS-3 scintillation solubilizer - Beckman 
Bovine serum albumin - Sigma. 
Carbosieve-B G.C. column support - 60/80 mesh - Supelco Co. 
Cellulose MN 300 TLC plates - Brinkman 
Diethyldithiocarbamate - Eastman 
DL-3,4-Dihydroxymandelic acid - Grade II Sigma 
3,4-dihydroxy phenylglycol - Sigma 
3,4-dihydroxytoluene .- Pfaltz and Bauer 
2,3-dimethoxyphenol - Aldrich 
Disulfiram (antabuse) - Tetraethylthiuramdisulfide - Ayerst 
Bis - 2,5-diphenyloxazole (PPO) - Scintillation Fluor - Beckman 
Dowex AG-50 Ion-Exchange Resin - Bio-Rad Labs-
Ellagic Acid Dihydrate - Aldrich 
Epinephrine HCl - Sigma 
Ethanol, 95% - Mallinckrodt 
Ethanol, Absolute-Commercial Solvents Corp. 
Folin reagent - Sigma 
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Gallic acid monohydrate - (3,4,5-trihydroxy benzoic acid) Aldrich 
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Gas chromatographs - Barber Coleman Model 5320, Varian Model 2100 
Gas chromatography glass columns - Lance Glass Works Inc. 
Beta-Glucoronidase Type II - Sigma 
Heparin Sodium Salt, Grade I - Sigma 
1,4-Hydroquinone - Eastman 
Ink (recorder) - Applied Science 
Ion-exchange glass columns - Ace glassware 
Kreb's Ringer's - phosphate buffer - NaCl, KCl, Mgso4 , 0.154 M 
each; Ca Cl2 0.11 M, Na2HP04 buffer pH 7.4 0.1 M. - Mallinckrodt 
Liquid scintillation spectrometer, Model LS-250 - Beckman 
DL-Methionine - Nutritional Biochemicals Co. 
3-Methoxycatechol - Aldrich 
Metrecal Shape liquid-Gazzola Drug Co. 
Microlance, Blood Lancet - Becton, Dickinson and Co. 
Micropipet, 20 microliters - DADE 
Beta-Nicotinamide Adenine Dinucleotide (NAD)-Grade II - Sigma 
Norepinephrine (Arterenol) HCl - Sigma 
7-3H-(DL)-Norepinephrine HCl - International Chemical and Nuclear Co. 
DL-Normetanephrine HCl - Sigma 
pH Meter - Model 12B-Corning 
Planimeter - Gelman Instrument Co. 
Porapak Q-S GC Column Support - 80/100 mesh - Waters Associates 
Propionaldehyde - Eastman 
Propylgallate - Aldrich 
Pyrogallol (1,2,3-trihydroxybenzene) - Sigma 
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RO 4-4602 - (N' - (DL-seryl)- N2-(2,3,4-trihydroxybenzyl) 
hydrazide - Hoffmann - LaRoche (gift) 
S-Adenosyl-L-Methionine chloride (70-80%)- Sigma 
Salsolinol HBr 98% - K and K Labs 
Scintillation bottles and polyethylene-lined screw caps-
Scientific Products. 
Septum, G.C. - Applied Science 
Serum Bottle 30 cc and Stopper - Scientific Products 
Shikimic acid - Aldrich 
Snoop Leak detector soap - Applied Science 
Spectrophotometer - Model Acta CIII-Beckman 
Syringe, Gas-tight - pressure-Lok A-2 - Pierce 
Tetrahydroisoquinolines (4,6,7-trihydroxy)- synthesized by M. Collins, 
" F. Kernozek. (1972). 
Tetrahydroxy - 1,4-quinone dihydrate - Aldrich 
Toluene, Scintillation Grade - Beckman 
1,2,4-trihydroxybenzene - Aldrich 
Vanillylrilandelic acid - (DL-4 -hydroxy-3-methoxy-mandelic acid)-
Sigma 
Zero Gases - Argon, Air, Helium, Hydrogen, Nit~ogen - Size lA-
Liquid Carbonic 
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B. METHODS 
I. IN VITRO CATABOLISM OF TETRAHYDROISOQUINOLINES 
Male Holtzman Sprague-Dawley rats, weighing 300-400 gm each, were 
injected with pyrogallol (PG) 250 mg/kg i.p. in 1 ml 0.9% saline or with 
0.9% saline only. One-half hour following pyrogallol or saline injection, 
rats were decapitated and livers and brains were removed and washed in 
cold Kreb's-Ringer's phosphate buffer pH 7.4. Homogenization was done 
with a chilled Teflon homogenizer in 2 volumes of ice-cold buffer which 
contained L-ascorbic acid, 0.5 mg/ml. To each homogenate containing 
500 mg of tissue was added lOOpmoles MgC1 2 (O.l ml), 2 nanomoles ( 1 FC) 
of the catechol substrate to be metabolized ( 1 pl), and a self-regener-
ating COMT cofactor system (Schweitzer and Friedhoff, 1969) consisting 
of 5 pmoles each of DL-methi.mine (0 .25 ml), adenosine triphosphate (ATP) 
(O.l ml) and S-adenosyl-L-methionine chloride (SAM) (0.1 ml). The solu-
tions of ATP and SAM were made immediately before addition to the in-
cubate because of their lability in solution. The total volume of each 
incubation mixture was 2.05 ml. 
Incubations were carried out in open 25 ml Ehrlenmeyer beakers 
in: a 37°C shaking water bath. Control incubations were either heat-
denatured homogenates (90°c, 5 min) or those without the added COMT co-
factors system. After 2 hours the reaction was stopped by deproteination 
with 1 ml 2N HCl and centrifuged at 10,000 g for 15 min at o0 c. The 
precipitate was washed once with 1 ml 2N HCl. Catechol compounds were 
separated from the non-catechol products using an aluminum hydroxide(AH) 
slurry method (Cohen, 1971). The supernatant and wash were combined in 
50 ml beakers to which 3 ml freshly-prepared AH was added. (The AH was 
composed of Al2 (so4)3·18Hi>,10% w/v adjusted to pH 8.3). The AH 
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suspension was shaken, centrifuged for 15 minutes at 10,000 g, washed 
twice in 1 volume 95% EtOH by resuspension and recentrifugation, and the 
non-catechol-containing supernatant was saved. The precipitate was then 
dissolved in 2 ml 4N HCl for 30 minutes, and the aluminum ions reprecip-
itated as aluminum phosphate by adding 1 ml kH2Po4 and adjusting to pH 
3.5 with lN NaOH. This step frees the catechol compounds into the super-
natant. After addition of 4 volumes of acetone: absolute EtOH (1:1 v/v), 
centrifugation is done for 20 minutes, the precipitate being resuspended 
and recentrifuged. The final supernatant had contained the free 
catechols, as confirmed by thin layer chromatography (vide infra). 
The radioactivity of a 1 ml aliquot of each fraction was measured 
in a solution of toluene: 2,5-diphenyloxazole: BBS-3 (Beckman; 100 ml: 
5 gm: 200 ml) by liquid scintillation spectrometry on a Beckman LS-250 
spectrometer. Thin-layer chromatography (TLC) with zonal scraping was 
carried out on aliquots of the fractions using the conditions described 
below for the 3H-TIQ sub~trates. Recovery was 70 ± 5%. 
The substrate TIQs were produced in lM NaOAc pH 6 buffer by 
condensation of 7-3H-d,l-NE with excess aldehyde, as described by Cohen 
and Collins (1970). Reaction with pre-distilled AcD gave as the major 
product, l-methyl-4,6,7-trihydroxy-1,2,3,4-TIQ (TIQ I,), while formal-
dehyde (HCHO) yielded 4,6,7-trihydroxy-1,2,3,4-TIQ (TIQ II) (Fig. 1 ) 
The extent of reaction was determined by iodochrome monitoring and by 
TLC. todochrqne monitoring consisted of oxidizing open-chain amines 
(e.g. CAs) with iodine to a pink color,. while cyclized amines such as 
TIQs turn yellow in solution. Aqueous solutions (2.5 cc) of each com-
pound (1 mg/ml) were tested at pH 7.0 by addition of 0.1 ml Na2s2o3 0.05N 
followed in two minutes by 0.2 ml Na2s2o3 0.05 N. The TIQs were then 
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separated from unreacted aldehyde by adsorption on aluminum oxide (Al 203) 
columns at pH 8.3) washing twice with distilled water) followed by elu-
tion with lN HCl. The eluates w~re then readjusted to pH 7.4 and again 
were subjected to TLC w~th zonal scraping for proof of purity, prior to 
addition to the homogenates. 3H-NE was prep~rified on Al2o3 in the same 
manner. 
TLC glass plates (20 x 20 cm) were coated with 0.25 mm Adsorbosil-
1, air-dried 20 minutes, and heat-activated for 30 minutes at ll0°c. 
Development was in sec-butanol: formic acid: water (15:3:2) under nitro-
gen atmosphere in a tank lined with solvent-saturated filter paper (TLC 
System A). A second TLC system (TLC System B) was also employed, using 
Brinkman cellulose MN 300 plates, 0.5 mm thick, developed in methanol: 
n-butanol: benzene: water (40:30:20:10). Visualizing spray reagents were 
potass~um ferricyanide (4,4 mg/ml in 0.2 M phosphate buffer, pH 8.3) fol-
lowed by ferric chloride (2.5% in water freshly mixed with 1.5 volumes 
of acetone). Unlabelled TIQ standards were co-chromatographed with the 
radioactive reaction products. These standards had been synthesized in 
this laboratory by established organic procedures and their identities 
confirmed by elemental analysis and nuclear magnetic resonance (Collins 
and Kernozek, 1972). 
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II. IN VIVO ACETALDEHYDE AND ETHANOL BLOOD LEVELS 
Non-fasted Holtzman Sprague-Dawley rats (300-400 gm) were given 
EtOH ( 2 gm/kg i.p.; 25% v/v) 1 hour after pyrogallol (PG) or saline. 
Tail blood samples (20 1ul) were taken at various intervals after EtOH 
injection by cutting the distal inch of the tail with a razor blade and 
milking it. AcD and EtOH blood levels were then estimated on a Barber-
Coleman 5320 flame ionization gas chromatograph (GC) by the method of 
Coldwell~ al (1971). In this technique, 2 cm square disks of #1 
Whatman filter paper were soaked in 0.2% sodium fluoride and then air-
dried. After placement of disks in 30 cc serum bottles, blood .samples 
were blown into the disks from heparinized 20;ul pipettes. With the 
pipette left in, the bottle was then closed with a rubber septum-centered 
stopper. Equilibration of vapors was achieved in a shaking water bath at 
35°c for 15 minutes. 
As the modifications of the GC technique, 2 cc headspace gas 
samples were injected into the GC, and 6' x ~" metal columns packed with 
Porapak QS (80/100 mesh, Waters Associates) were used. Conditions 
employed for Porapak were gas flows (ml/min) for nitrogen, hydrogen, air, 
100, 30, 300, respectively; column temperature, 1450C., injector tempera-
ture, 200°c; detector temperature, 210°C; retention times were determined 
(Fig 2 ) . 
All other compounds tested for their effect on EtOH and AcD levels 
were injected into the animals in the same manner as PG, being dissolved 
inunediately before injection in distilled water, in order to minimize any 
changes in aqueous solution. 
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' III. IN VITRO DISAPPFARANCE OF ACETALDEHYDE 
Before testing for inhibition of the semi-purified ALDH, and 
exploratory experiment was perfonned to examine whether pre-injection 
with PG would decrease the rate of disappearapce of AcD added to rat 
liver in vitro. AcD 0.33 mM and NAD 0.33 mM were injected through the 
rubber stopper of a 30 cc serum bottle containing 1 ml rat liver homoge-
nate (1:1 v/v in pH 7~4 sodium pyrophosphate 0.1 M). The liver tissue 
was obtained from rats injected one hour pre-sacrifice with PG (250 mg/kg) 
or saline (control). Incubation of the homogenate was for 30 minutes in 
a 37°c. shaking water bath. Samples of vapor were taken at 5, 10, 15 and 
30 minutes and measured by gas chromatography. For each sample, the 
level of AcD at 30 minutes was subtracted from the maximal level of AcD 
observed. 
This experiment was conducted to determine by gas chromatography 
if AcD disappearance (oxidation) was slowed by in vivo PG. The results 
indicated that indeed it was, thus substantiating the in vivo experiments 
with injected AcD, reported by Collins et al, 1974 Therefore, it 
seemed f~asible to further examine liver ALDH (vide infra). 
r 
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IV. IN VITRO ASSAY OF ALDEHYDE DEHYDROGENASE* 
The intramitochondrial assay for ALDH was done using the method 
of Dietrich and Erwin (1971) • Immediately after the decapitation of 
four male Holtzman rats weighing 350 gm each, the livers were removed 
and cut into small pieces, fibrous structures being removed at this time. 
All procedures were carried out at or below 4°C. The tissue was made 
into a 10% v/v homogenate in 0.32 M sucrose with 10 strokes of a teflon 
homogenizer. After centrifugation for 10 minutes at 750xg in 50 cc poly-
allomer tubes, the precipitate was discarded and the supernatant was 
centrifuged at 20,200xg for 15 minutes. The resulting supernatant was 
discarded and the mitochondrial pellet resuspended to the original volume 
by manual homogenization with the teflon homogenizer. Centrifugation at 
20,200xg for 15 minutes was again done. The precipitate was resuspended 
to a final volume of 100 ml in 0.05M NaH2P04 pH 7.4. This mixture was 
sonicated in a 250 ml beaker for four 1-minute periods with 3-minute 
cooling intervals between each, using a Branson sonifier model LS-75, 
setting 7, amperage 7. The sonicate was centrifuged at 37,000xg for 15 
minutes, saving the clear supernatant at o0 c for the ALDH assay. 
The assay was conducted using a Beckman ACTA Clll Recording 
Spectrophotometer, the absorbance of the NADH formed from NAD being 
monitored using the tungsten lamp at a wavelength of 340 nm. Settings 
were as follows: dynode voltage 600, scan speed 1 run/sec., chart expan-
sion 50 nm/inch, span 0.1, dwell 2.5 sec., interval 15 sec., shutter 
standard and reference open • 
The concentration of protein in the enzyme preparation was per-
formed according to Lowry ( 1962). The reagents used were: (A) Na2co3 
* Carried out in the laboratory of Dr. Boris Tabakoff, Dept. of 
Biochemistry, Chicago Medical School. 
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2% in 0.1 N NaOH; (B) Cuso4 . HzO 0.5% in 1% sodium citrate; (C) reagent 
(B) 1 ml plus reagent (A) 50 ml; (D) Folin commercial reagent diluted 
with water to give a solution of lN. To each test tube is added 0.05 ml 
sample,0.65 ml water, and 1 ml reagent C. The tube is mixed by vortex 
and is left at room temperature for 10 min. Reagent D (O.l ml) is added 
rapidly to each tube which is vortexed. Samples may be read after 30 min 
at an excitation wavelength of 750nm on a Beckman Acta Clll spectrophoto-
meter. Control samples were, made from solutions of bovine serum albumin. 
All solutions were kept in ice immediately after preparation. 
The assay mixture contained 0.2 ml enzyme (0.50 mg/ml),0.1 ml 
inhibitor, and the following components given with their final concentra-
tions: 0.1 ml NAD 0.001 M, 0.1 ml NaH2Po4 0.05M pH 7.0, 0.1 ml propion-
aldehyde substrate 0.002 M, brought up to a final volume of 1.0 ml with 
distilled water. 
Although the pH optimum for ALDH is 9.6-10.0, the pH of 7.0 was 
used to minimize the oxidation of PG and other compounds tested for 
inhibition. The slight oxidation of PG that occurs in the first 5 min 
(3-minute warm-up time and 2-minute reaction time) was substracted by 
using a control sample containing PG with no propionaldehyde substrate. 
Most of the oxidation of PG in the 25°c experimental conditions used 
seemed to occur after 10 minutes, as evidenced by an increasing peak of 
absorbance at the wavelength setting used. This, however, occurred too 
late to affect the experimental results. 
Quartz cuvettes of 1.5 ml volume were used, being rinsed once 
wi~i1 EtOH and thrice with water after each reaction. After a 3-minute 
adaptation period in the dark at 25°c in the machine, the reaction was 
started by the addition of propionaldehyde, followed by mixing each 
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reaction twice with a clean Pasteur pipette. The maximum velocity in 
O.D. units for the first 100 seconds of reaction time was recorded, and 
converted into moles NADH/min/mg protein by using the conversion factor 
-9 
of 32.8 x 10 • This conversion factor included the extinction coeffi-
cient for NADH, which is 6220 moles per liter. The average velocity of 
three samples at each concentration of inhibitor, while varying NAD and 
propionaldehyde concentrations, was computed and plotted in a double 
reciprocal graph of velocity versus substrate concentration (Lineweaver 
and Burk, 1934). Linear regression analysis, computed on an Olivetti 
Programma 101, gave the corresponding values of l/Vmax and -1/Km. 
The structures of compounds tested for inhibition of ALDH are 
shown in Fig. 12. 
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v. CHRONIC ALCOHOL DRINKING MODELS 
The animal model used here for voluntary alcohol ingestion was 
reported by Freund in 1969 using mice. The diet is shown in Table 1. 
Two hundred male ICR-DUB mice (Scientific Small Animals Farms) 
weighing 25-35 gm, were housed separatelY'~, given daily water and 1.5 gm 
of Purine rodent lab chow (about 1/3 normal voluntary intake). After 
nine days, weights were found to be reduced 25-30%, and animals were 
then started on a diet of ad lib EtOH in Metrecal or on isocaloric 
sucrose-Metrecal solution, either diet being the sole source of food. 
Animals were observed for gross signs of intoxication for 5 days, at 
which time they were withdrawn from EtOH-Metrecal diets onto isocaloric 
sucrose-}fetrecal diets. They were then sacrificed after 1-2 days of 
withdrawal. Animals had been graded behaviorally as to their degree of 
intoxication and withdrawal severity, as shown in Table 2. Animals were 
sacrificed at the proper times to represent each of the following groups: 
(1) weight-reduced, (2) weight-reduced plus intoxicated with EtOH, (3) 
weight-reduced, intoxicated, plus withdrawn onto sucrose, (4) weight-
reduced plus sucrose feedingfur the entire experiment, and (5) controls, 
which were fed lab chow ad lib and then sacrificed before weight-reduction 
or special diets. 
Since it was discovered that EtOH-drinking mice (Tables 12 and 
14) drank a lesser daily volume and regained less of their reduced weight 
* Performed in the laboratory of Dr. Charles Scudder, Loyola University 
of Chicago. 
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conducted in the next experiment, which involved rabbits. This involved 
measuring the daily intake of the EtOH-drinkers drinking ad lib, and 
then feeding no more than that amount to the sucrose controls on the 
following day. Thus, the question of differential nutrition between 
the experimental and control groups would be ruled out as a source of 
problems. 
Ten-week-old male New Zealand white rabbits were housed singly 
and for one week were fed water and Purina rabbit chow ad lib. 
For 80 days, six animals were fed liquid diets as the.sole 
source of calories. Cage bottoms were of mesh, allowing feces to fall 
from the cage and not be reingested. EtOH diets were composed of 
Metrecal Shape chocolate drink plus 95% EtOH. The three corresponding 
control animals were given isocaloric sucrose substituted for EtOH, and 
each was pair-fed the average volume of diet consumed by the three 
experimental animals on the previous day. Freshly mixed food was of-
fered daily in pottery bowls to avoid the problems previously encoun-
tered: spoilage, which occurred to some extent with the mouse exper-
iment, and tube plugging due to sedimentation, which also occurred fre-
quently in the mouse experiment, even with larger-bore tube openings, 
thus precipitating withdrawal or starvation as a complication of 
technique. Gas chromatographic testing of the EtOH-Metrecal solutions 
in open pottery bowls showed negligible loss of EtOH to evaporation over 
24 hr at room temperature. 
Blood samples were taken from the ear vein of each rabbit, 
including controls, at about 11 A.M. daily or every other day. The 
samples were then measured for concentrations of EtOH and AcD with the 
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flame-ionization detector of the Barber-Colman GC Model 5320 as described 
previously for rat experiments. 
Animals were changed to clean cages weekly. Cage-cleaning, 
feeding, blood-sampling and weekly weighing were all performed in a 
random order among the animals in order to minimize differences in 
handling. 
Each experimental animal drank EtOH-Metrecal ad libitum from 
500 ml daily servings, which none of them over completed. In this diet, 
EtOH initially comprised 35% of the calories, or 6.0% volume/total 
volume (v/tv) concentration. The EtOH concentration was slowly 
increased by steps over eighty days until it reached 20% v/tv, or 71% 
of total calories (Table 14). 
All animals were allowed to eat until the end of the experiment, 
and thus withdrawal effects were not sought. After 80 days, animals 
were sacrificed by decapitation and the livers removed, washed and 
placed in formalin. Livers were then sectioned for light microscopy 
and stained with hematoxylin and eosin. 
As the results indicate, only minimal intoxication was seen, so 
attempts to induce withdrawal seemed futile, contrary to the mouse 
experiment. 
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RESULTS 
A. SYNTHESIS AND THIN-LAYER CHROMATOGRAPHY OF TETRAHYDROISOQUINO-
LINES 
Table 3 shows the results of iodochrome monitoring of CA-
aldehyde condensation reactions. The reaction times for HCHO plus CAs 
were several times faster than those for AcD plus CAs. NE reacted more 
rapidly with either aldehyde than did EPI. The fastest reaction was 
that of NE plus HCHO (5 minutes), while EPI took 35 minutes to complete-
ly react with AcD at the conditions used. 
The results of thin-layer chromatography of NE and related com-
pounds are listed in Table 4. Two separate solvent systems were 
employed to confirm the results. Standard compounds included NE, its 3-
0-methylated product normetanephrine (NM), TIQ I (NE-AcD), TIQ II (NE-
HCHO), and the 6-0-Methylated products for each of the TIQs. The degree 
of migration was measured by Rf, the ratio cf the distance between the 
compound and the origin, divided by the distance between the solvent 
front and the origin. 
From the highest to the lowest migrating substances, the results 
were: System A, NM, 6-0-Me-TIQ I, NE, TIQ I, 6-0-Me-TIQ II, and TIQ II; 
System B, NM, TIQ I, 6-0-Me-TIQ II, 6-0-Me-TIQ I, NE, and TIQ II. With 
the exception of TIQ I on System B, each catechol compound was separated 
from its corresponding 0-methyl compound by an Rf value of 0.06 to 0.10. 
B. IN VITRO CATABOLISM OF TETRAHYDROISOQUINOLINES 
The in vitro catabolic products of 3H-NE or 3H-TIQs were studied 
following the two hour incubation. A decrease in adsorption of radio-
active label to the catechol-binding Al203 column indicated a conversion 
to non-catechol metabolites. 
Metabolism of the two TIQs was qualitatively different from that 
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of their NE "precursor." Non-catechol portions from incubations of brain 
or liver tissue with TIQ II consistently showed only one radioactive TLC 
zone which co-chromatographed with a synthesized standard of the expect-
ed 0-methylated metabolite, 4,7-dihydroxy-6-methoxy-TIQ. Similarly, non-
catechol effluent from incubations of TIQ I with either tissue demonstra-
ted a single radioactive zone-co-chromatographing with a synthetic stan-
dard of the expected l-methyl-6-0-methylated product (Fig. 10). 
When examined by TLC, the non-catechol portions from NE incuba-
tions, contained radioactive normetanephrine and radioactive 0-methylated 
products migrating with standards of 3-methoxy-4-hydroxyphenylglycol and 
vanillylmandelic acid; these deaminated non-catechol products are includ-
ed in the total percentages for NE products in Table 5. 
For either TIQ, the catechol portions contained radioactivity 
apparently associated only with unreacted substrates. Thus, it appeared 
in these studies that formation of possible products of MAO action on 
these TIQs, as had occurred with NE, was insignificant for these alkaloids. 
As shown in Table 5, 0-methylation in brain homogenates proceeded 
to a similar degree for all three catechol substrates. Metabolism of TIQ I 
(21.5 ± 6.1%), however, was slightly but significantly less than that of 
NE (33.6 ± 4.6%). Liver, on the other hand, was found to metabolize 
these substrates in a somewhat reverse order, TIQ I > TIQ II > NE 
(78.2 + 8.3, 58.l ± 4.5 and 35.3 ± 4.6%, respectively). 
Comparing the two TIQs, the AcD-derived TIQ I was a better sub-
strate for liver COMT than was the HCHO-derived TIQ II, while the two 
were not appreciably different in brain tissue. Pyrogallol inhibited 
the 0-methylation in liver of TIQ II (89.4%) more than that of TIQ I 
(60.4%), but the relative extents of inhibtion were reversed in brain 
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tissue (TIQ I,90.7%; TIQ II; 73.1%). (Fig. 3 and 4) 
The conversion in vitro of the substrates to glucuronide products 
~vas apparently ruled out by incubation of the homogenate products with 
B-glucuronidase for 4 hours resulting in no change in the TLC and column 
radioactivity patterns. Possible oxidation of the substrates to quinone 
products was countered by the addition to the incubation mistures of 
ascorbic acid. 
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c. EFFECT OF PYROGALLOL ON IN VITRO ETHANOL AND ACETALDEHYDE 
BLOOD LEVELS 
Using the microtechnique described (vide supra), separation of 
AcD, EtOH, and acetone was attained on a Porapak QS column (Fig. 2). 
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Relative retention times were as follows: AcD 1.0, EtOH 2.1, Acetone 2.6. 
Peak heights were found to be directly proportional to peak 
volumes (measured by planimetry) in the concentrations used, so that 
peak heights were used for conversion to AcD or EtOH concentrations. 
Figure 5 shows Porapak calibration curves prepared for the estimation 
of blood AcD and EtOH, respectively. Acetone was not seen in the blood 
of rats injected with EtOH or AcD,although it has been reported to 
exist under such conditions (Coldwell et al, 1971). 
Table 6 illustrates the effect of PG pre-injection on the in vivo 
blood levels of AcD and EtOH in rats injected with EtOH 2.0 g/kg. PG 
potentiated the AcD levels, the concentrations, of AcD being increased 
significantly (p < 0.05) at 60, 120, 180 and 270 min. Comparing saline-
injected rats to PG-injected rats, the AcD blood concentrations at these 
times were increased (pg/ml) by PG from 2.6 ± 0.5 to 4.8 ± 1.2, from 
+ + + + + 2.0 - 0.4 to 4.1 - 1.6, from 1.0 - 0.2 to 3.6 - 1.2, and from 0.3 - 0.1 
+ to 1.9 - 0.4, respectively. 
EtOH levels were increased slightly by PG, from a maximum saline 
+ + level of 1700 - 400 pg/ml to 1900 - pg/ml. The increase of EtOH 
concentration caused by PG was not significant when the saline and PG 
values were compared either maximum vs. maximum (1700 vs. 1900) or time 
vs. time (60 minutes saline vs. 60 minutes PG, 120 vs. 120, etc. 
The administration of PG to rats was noticed to result in darken-
ing of the blood from the normal bright red color seen following saline 
injection, to dark red, purple or reddish-brown. 
D. EFFECT OF PYROGALLOL, PYROGALLOL ANALOGUES AND METABOLITES, AND 
DIETHYLDITHIOCARBAMATE ON ALDEHYDE DEHYDROGENASE IN VITRO 
The results of a preliminary screening experiment on the effect 
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of PG on AcD metabolism in vitro is shown in Fig. 11. The rate of dis-
appearance of AcD in rat liver was diminishe~ after pre-injection with PG. 
The AcD peak height was significantly increased (p < 0.01) by PG at 15 
and 30 minutes. 
A sample spectrophotometric recording of the ALDH assay is shown 
in Fig. 6, denoting typical results seen upon testing an inhibitor of 
the enzyme. The effect of PG on ALDH activity in vitro is demonstrated 
in the two graphs of Fig. 7 and 8. The double reciprocal plots of 
activity versus NAD or propionaldehyde concentrations indicate a mixed 
inhibition by PG with respect to both compounds. 
The binding of PG was reversible, as demonstrated by the dilution 
method. Aliquots of PG plus enzyme which were allowed to stand for 5 
minutes to permit possible binding of PG to enzyme, and were added to 
the assay mixture. Thus, if PG were irreversibly bound to enzyme, the 
PG-enzyme aliquot would not inhibit the assay activity. However, such 
evidence for irreversibility was not seen (Table 7). Instead, PG-enzyme 
aliquots added to the assay caused inhibition of activity equal to the 
inhibition caused by the same concentration of PG added alone. Thus, 
the binding of PG was apparently of the reversible nature. 
Various control samples were employed to demonstrate the verity 
of the observed inhibition by PG (Table 7). Several samples contained 
all assay components except one, ruling out artifactual results. Other 
samples were pre-incu.bated with PG for 3,5,10 or 15 minutes at room 
temperature before propionaldehyde was added, as compared to the normal 
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3 minute warm-up to room temperature. The results from these samples 
showed that pre-incubation for up to 15 minutes does not effec the 
inhibition of ALDH by PG. Thus, a possible inhibitory role for an 
aqueous degradation product of PG is apparently disallowed. 
In Table 8, the effect on ALDH of PG'and structural analogues 
is seen. The strongest inhibitors appear to be PG, 1,2,4-trihydroxy-
benzene, hydroquinone, RO 4-4602, diethyldithiocarbamate and 3-methoxy-
catechol, all of which caused > 15% inhibition at 5 x l0-4M. The 
remaining compounds, gallic acid, 2,3,-dimethoxyphenol, propylgallate, 
shikimic acid, 3,4-dihydroxytolvene, and tetrahydroxyquinone, inhibited 
either mildly or not at all. 
Table 9 compares the effects of various drugs on ALDH activity 
in vitro, to their in vivo effects on EtOH-derived AcD blood levels. 
PG, DDC, and RO 4-4602 were both in vitro inhibitors and in vivo 
potentiators in these experiments, while hydroquinone, 3-methoxy-catechol 
and 1,2,4-trihydroxybenzene had in vitro but not in vivo effects. Gallic 
acid and 2,3-dimethoxyphenol had no observable effects on either system. 
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E. CHRONIC ALCOHOL DRINKING MODELS 
1. MOUSE EXPERIMENTS 
The behavioral effects on male mice of ingestion cf the EtOH-
Metrecal diet are indicated in Table 2. All animals became intoxicated 
to some degree, approximately one-fourth reaching the ataxic stage, 
one-fourth the comatose stage, and one-half achieving intermediate 
severity of intoxication. The study of Freund (1969), by comparison, 
resulted in only intermediate and maximal stages of severity of intox-
ication, with 50% of animals in each group. All of Freund's animals 
surpassed the initial ataxic stage of intoxication. 
A major behavioral difference in the two studies on mice was in 
the extent of withdrawal symptoms observed, as shown in Table 2. None 
of the mice died during convulsion, as opposed to 10% of those of 
Freund; in fact, only one of the 28 mice in the experimeris described 
here even reached the convulsive stage, compared to 60% of Freund's 
animals that had tonic-clonic convulsions. The second stage of with-
drawal, that of tail-beating, etc., was achieved by 2 of 28 and 3 of 10 
of the mice in this study and Freund's study, respectively. Both of 
the animals reaching the second stage of withdrawal in our experiment 
exhibited tail-beating, stereotypy, retropulsion, broad-based gait and 
the tail-to-nose maneuver, the latter commonly known as the "Straub tail'.' 
Possible toxicities or hyponutritive qualities of the Metrecal 
diets were examined by measuring the weight changes (Table 10) and the 
number of deaths (Table 11) during chr6nic Metrecal drinking in mice. 
Approximately 3% (5 of 180) of mice died during the phase of 25-30% 
weight reduction before the Metrecal diet was instituted. Another 8 
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animals expired during the five days of drinking the EtOH-Metrecal com-
bination. Three of these animals died with their limbs extended, pos-
sibly denoting death during convulsion, according to Freund (1969). No 
mice died during the withdrawal of EtOH onto isocaloric sucrose or while 
on the sucrose-Metrecal diet that followed weight reduction. 
The change in the weights of mice while on the two Metrecal diets 
is shown in Table 12. Measuring the change in body weight from the end 
of the weight reduction period to the end of the Metrecal regimens, the 
EtOH group was seen to lose an additional 4.4% while those drinking 
sucrose regained 14.6% of their weight. 
The daily volume of Metrecal diet consumed ad lib by mice, in 
Table 13, shows a doubling of consumed liquid diet by the sucrose group 
compared to the consumption of the EtOH group. 
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2. RABBIT EXPERIMENT 
In the rabbit experiment, EtOH consumption (Table 14) almost 
doubled following the gradual doubling of EtOH-derived calories from 
35% to 71%. The greatest changes in consumption were seen to occur in 
the lower ranges of EtOH concentration. Increasing EtOH from 6.0 to 
7.5% v/v and from 7.5 to 10.0% v/v caused the highest changes of about 
5-6 ml/day. Concentrations of EtOH above 10.0% did not contribute as 
much to an increase in consumption. 
Table 15, indicates the physical changes seen while the animals 
were fed either of the liquid diets. Massive loss of body hair was 
seen in two-thirds of both the EtOH- and the sucrose-drinking groups. 
The hair loss was heaviest on the underside and on the legs, and began 
to occur within 14 days after the experiment was begun. A nutritional 
basis may have existed for this hair loss, since· fur mites could not 
be detected from microscopic examination of skin scrapings from affect-
ed areas of any animal performed by Dr. Fred Buddingh of the Animal 
Research Facilities, Loyola University. 
Weight loss or sub-normal weight gain was seen in both the EtOH 
and sucrose groups (Table 12). Actually, five of these six animals 
gained a small percentage of their original ten-week-old weight during 
the 80-day experiment. However, their litter mates eating normal lab 
chow and water ad lib increased their body weights by 70%. 
The· only death occurred in a sucrose control rabbit on day 76. 
This animal had shown extensive hair loss over a period of weeks and 
finally became listless and ceased to eat 2 days before its death. None 
of the ethanol-treated animals expired (Table 11). 
Gross intoxication was never observed in the ethanol-drinking 
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rabbit (except for a few days early in the experiment). Animals were 
observed inside and outside of the cages for ataxia and for stuporous or 
comatose qualities. 
a) Blood levels of ethanol and acetaldehyde 
Ethanol and acetaldehyde blood levels are shown in Fig. 9 
Neither compound was ever observed in the blood of sucrose animals. In 
the ethanol group, ethanol levels ranged from 0-100 mg/100 ml of blood 
(mg%) during most of the experiment, although the blood ethanol of an-
imal 1 rose to 200-400 mg% while drinking the 10.0% ethanol solution and 
returned to normal within 10 days. It was during this period that we 
observed increased ataxia, daytime eye-closure, and warmth and redness of 
the ears in this animal. 
The pattern of blood acetaldehyde levels usually resembled the 
blood ethanol variations, the acetaldehyde fluctuating from 0-30 pg/ml 
but usually below 9 ,ug/ml. However, when 17 .5/, and 20.0% ethanol solu-
tions were fed to the animals, large increases occurred in the blood 
levels of both EtOH and AcD. 
b) Liver Pathology (Figs. 13 and 14) 
Hematoxylin - and eosin - stained liver sections performed by 
Dr. Buddingh, showed severe fatty changes throughout the livers of an-
imals on the EtOH-Metrecal diet. The livers of sucrose-Metrecal-fed an-
imals displayed negligible or no fatty change, while the animals on 
normal lab chow had normal hepatic architecture. No other hepatic pathol-
ogy, such as hepatocyte swelling, was observed. No electron microscopy 
was performed. 
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DISCUSSION 
A. OVERVIEW 
These studies were concerned with several related aspects of 
the biochemical bases of alcohol dependence. TIQs, hypothesized to be 
aberrant CA "metabolites" during alcoholism, were investigated as in 
vitro substrates for the important CA-metabolizing enzymes, COMT and 
MAO. Secondly, when in vivo rat intoxication experiments were initiated, 
it was noted that PG pre-injection caused AcD blood levels to be signif-
icantly elevated. The mechanism of this elevation was explored briefly 
, in vivo and in greater detail in vitro with purified rat liver ALDH. 
Concurrently, chronic alcoholic mouse and rabbit models were studied. 
Various parameters were gauged in these studies, including signs 
of gross intoxication, rabbit liver cytoarchitecture, and rabbit blood 
levels of AcD and EtOH. 
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B. IN VITRO CATABOLISM OF TETRAHYDROISOQUINOLINES 
In the TIQ cataboli'c experiments with liver tissue, a-methylated 
products derived from NE were always formed to a lesser extent than were 
a-methylated products from either TIQ. These findings were in accord 
with the report of the metabolism by rat liver COMT of the l-methyl-6,7-
dihydroxy-TIQ, salsolinol (analogous to TIQ I without the aliphatic 
hydroxy group). A. Collins et al (1973), found salsolinol to be a better 
substrate in vitro for COMT than the parent amine, DA. Salsolinol was 
also seen to serve as a moderate competitive inhibitor of COMT in vitro 
(A. Collins et al, 1973). In our work, a further observation can be made 
that the 1-methyl group of TIQ I seemed to increase 0-methylation in 
liver compared to TIQ II, but made no significant difference in the brain 
metabolism of the two alkaloids. Although TIQ I is methylated on the 
1-carbon atom, it is a 2° amine; our results can be compared to those of 
Creveling et al (197a) which indicated a higher affinity of COMT for the 
2° amine ,E, than for the 1° amine, NE. However-, .Axelrod and Tomchick 
(1958) found the substrate specificity of COMT to be roughly equal for E 
and NE. 
Pyrogallol inhibition was quite variable in its extent and was 
never complete. In an earlier work by Crout (1961), 90-100% inhibition 
of semi-purified COMT was achieved after injection of PG 200 mg/kg, some 
50 mg/kg below our level. PG inhibition of COMT in our system never 
reached 100%, possibly for some or all of the following reasons: (1) PG 
is itself a known substrate for COMT and was partially consumed during 
the experiments; (2) PG may be oxidized to an inactive quinone during 
the long incubations, despite the addition of ascorbic acid; (3) different 
COMT isoenzymes act in both tissues and respond differently to the 
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inhibitor (although Rock~ al (1970) reported this not to be the case); 
(4) other 0-methylating enzymes which are PG-insensitive acted upon the 
substrates; or (5) endogenous activators of COMT or inhibitors of the 
actions of PG might have been present in the homogenates. 
It was also noted that inhibition of 0-methylation was consis-
tently 10%-40% greater for the TIQ substrates than for NE. Differences 
in the relative affinities of the various substrates and their respective 
products for the COMT-SAM complex may be responsible for this latter 
effect. 
Although 6-0-methylation was apparently seen and is expected 
because of the analogy to the predominant meta-0-methylationF.i.g.12 of the 
parent CAs cited in the literature, 0-methylation of the TIQs on the 7-
rather than the 6-hydroxyl group is possible. Creveling ~ al (1972) 
have reported 7-0-methylation of (DA-related) 6,7-dihydroxy-TIQs by high-
ly purified COMT preparations. In order for a 7-methoxy-4,6-dihydroxy-
TIQ to have been present in our homogenates, its TLC migration would 
have to be identical to that of its 6-0-methyl isomer, which is possible. 
A. Collins et al (1973) also commented on the lack of separation of 
various TIQs by TLC. However, the possibility of 7-0-methylation of the 
4-hydroxylated (NE-derived) TIQs should be examined with gas chromato-
graphic systems which separate the 6- and 7- isomers. 
It has been mentioned in Results that MAO action on these TIQs 
appeared to be insignificant in our homogenates. However, the product of 
MAO action on TIQs is unknown, whether it be ring-breaking to allow 
deamination or some other means. But one simple TIQ thus far, salsolinol, 
has been reported to inhibit MAO competitively (A. Collins~ al, 1973), 
as has a tetrahydro-beta-carboline (Mc Isaac g_t. al, 1972). The question 
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of whether these compounds are structurally altered during this compet-
ition remains to be determined. It is possible that MAO products of TIQs 
did form under our conditions and co-migrated with other TIQs, thus 
mask~ng their identity. It was our original intent to look for such 
products of TIQs, but unfortunately the structures of such postulated 
products or intermediates are presently unknown, and thus the organic 
synthesis of standards was not attempted. More than likely, however, 
added oxygen, the limitirg factor reported for MAO by some investigators 
(Achee et al, 1972), was possibly necessary to allow maximum MAO activity 
~lthough the presence of deaminated metabolites of NE in our system was 
evidence for the existence of some MAO activity in our homogenates). 
In the studies reported here, the formation of an 0-quinone from 
a 4,6,7-trihydroxy-TIQ by non-enzymatic oxidation was probably eliminated 
by the addition of the antioxidant, ascorbic ac~d. Moreover, simple 
quinone standards were found to migrate close to the origin in the TLC 
systems used, and little radioactivity was seen in that area. Conjuga-
tion by glucuronyl transferase can also occur, theoretically, but only 
in vivo, according to Axelrod (1958) , since they found that in vitro 
systems require cofactor addition. In support of this, the incubation 
of our homogenate products with beta-glucuronidase produced no clear 
changes in the TLC or column radioactivity patterns. 
In regard to exploratory in vivo studies, the facile 0-methyl-
ation of CA-derived TIQs should be taken into account by investigators 
concerned with TIQ detection and isolation •. Difficulties experienced 
in detecting TIQs in vivo could be due to their active conversion to 0-
methylated (and perhaps conjugated) metabolites. Indeed, gas chromato-
graphic studies by Bigdelli and Collins,(1973) show that, in rats acutely 
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intoxicated with EtOH, TIQ derivatives are detectable in brain and 
adrenal tissue when COMT is inhibited and AcD is elevated with PG. 
Physiologically, such CA-aldehyde condensation products may 
enhance NE and DA activity by acting as competitive COMT inhibitors 
71 
or by reducing available COMT cofactor, SAM. Single doses of L-DOPA 
have been reported to act in the latter manner, that is, as a cofactor 
depletor (Wortman et al, 1970). Hence, a metabolic relationship might 
exist between the formation of TIQs from aldehydes and CAs, and certain 
neurological aspects of chronic alcohol toxicity or of the alcohol 
withdrawal syndrome. 
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C. PYROGALLOL AND IN VIVO ACETALDEHYDE AND EtOH BLOOD LEVELS 
The mechanism by which PG potentiates blood AcD levels following 
injection of EtOH or AcD may be a complex one. Several possibilities were 
_examined, leaving us with the belief that inhibition of ALDH was a log-
ical mechanism, even though PG had never before been reported to possess 
such a property. 
Among the possible mechanisms of AcD potentiation, it was first 
thought that the primary known property of PG, (1) COMT inhibition, was 
predominant reason. Possibly an indirect mechanism of action of PG, that 
of inhibition of COMT and subsequent competitive inhibition of aldehyde 
dehydrogenase by the presumably potentiated catecholaldehydes, was at 
the root of the AcD elevation. Since in vivo detection methods for the 
catecholaldehydes are not yet developed, direct evidence of their poten-
tiation was not achievable. However, administration of other known COMT 
inhibitors -- tropolone, pyrocatechol (Molinoff and Axelrod, 1970), and 
3,5-dihydroxy-4-methoxybenzoic acid (Nikodejevic et al, 1970)-- was found 
to have no significant effects on AcD levels. Thus, inhibition of COMT 
appears to be unrelated to the ability of PG to elevate EtOH-derived AcD 
levels (Collins et al, 1974). (2) It was considered possible that the 
0-methylated products of PG, 3-methoxycatechol and 2,3-dimethoxyphenol 
(Archer et al, 1960), may be the actual elevators of AcD blood levels. 
--
However, these compounds did not affect blood AcD when given one hour 
before the administration the-EtOH. (3) A possible quinone oxidation. 
product of PG could be active in affecting AcD levels. PG is known to 
oxidize in aqueous solutions at room temperature, especially at alkaline 
pH. Thus, the effect of hydroquinone pre-injection was examined, but 
this compound was also ineffective in elevating EtOH derived AcD. There-
fore, if PG is converted to any appreciable extent in vivo to the 
quinone fonn, it was probably not in this fonn that PG exerted its ac-
tion on AcD levels. Purpurogallin was not tested in vivo. 
(4) Another possibility considered was an anti-oxidant or a 
general cytotoxic effect of PG. It seems unlikely, however, that PG 
would specifically affect the oxidation of AcD without slowing that of 
EtOH as well. As for the idea of cytotoxicity, the activities of EtOH 
catabolic enzymes seemed unaffected, since the EtOH turnover pattern 
appeared to be unchanged by PG pretreatment. Furthennore, Crout et !!! 
(1960) examined . the metabolism of tyramine, which is metabolized by 
enzymesother than COMT, and found that PG pretreatment appears to have 
no general cytotoxic or omnienzyme-inhibitory power. 
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(5) PG potentiation of blood AcD levels may be via stimulation of 
EtOH oxidation. PG is suspected to be a potent H2o2-stimulating agent 
in aqueous solution (Heikkila, 1972). EtOH oxidation via hepatic catala-
se, "peroxidatic oxidation ," (Thunnan et al, 1972; Oshno §!.·al, 1973) 
would be stimulated by this newly-generated cofactor H2o2 • If modulation 
of catalase activity is involved, PG may be an important drug for detail-
ed studies on the extent of the role of this enzyme in EtOH oxidation, a 
hitherto controversial topic. Speaking against this postulated mechanism 
of PG action would be the fact that such 11 induction11 occurs very soon 
after only a single dose of PG, which seems unlikely for enzyme induction 
or act.ivation. Actually, enzyme inhibition, unlike induction, could 
occur much more rapidly and would not r~quire synthesis of new enzyme. 
Moreover, EtOH turnover appeared to be unchanged after PG injec-
tion, arguing against an enhanced rate of EtOH catabolism. Also, a large 
increase in AcD blood level was seen after injection of AcD alone fol-
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lowing PG, imply:irg that a great part, if not all, of the PG-induced AcD 
elevation is due to an action of PG on AcD catabolism (Collins et al, 
1974 ). 
Finally, aminotriazole, shown to inhibit hepatic catalase effec-
tively at the dose given (Margoliash and Novogrodsky, 1958), did not 
lower the PG-potentiated AcD blood level (Collins et al 1974 ). This 
again implies that activat:icn of catalase appeared to play no major role 
in the action of PG. 
It has been argued recently by Feytmans and Leighton (1973), 
that the role of peroxidation of EtOH is minor in the rat after acute 
administration, since inhibition of ADH activity by pyrazole effects a 
strong inhibition of EtOH oxidation. However, these authors admit that 
HzOz generation is the rate-limiting factor for peroxidation, while the 
catalase content of the liver is in excess even to metabolize all the 
EtOH the rat can oxidize. Thus, a compound which generates large amounts 
of Hz02 , as PG may, could increase the EtOH-oxidizing activity of catal-
ase to a significant degree. The lack of effect of aminotrlazole on the 
PG-induced elevation of AcD may only mean that aminotriazole dosage was 
not large enough to overcome the greatly stimulated catalase activity 
created by PG-derived Hz02 • Although aminotriazole 1 gm/kg has been 
reported to cause 90-100% inhibition of hepatic catalase (Margoliash and 
Novogrodsky, 1958), it may not do so under conditions of vigorously in-
creased H2o2. levels. This question should be examined experimentally, 
possibly using higher dosage of aminotriazole and measuring blood H2o2 • 
(6) An inhibition of aldehyde catabolism, probably through ALDH, 
may well be a significant mode of action of PG. As such, it would ex-
plain the similarities in the effects on blood AcD and EtOH levels of 
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both PG and the known ALDH inhibitor diethyldithiocarbamate ( Collins 
et al, 1974). 
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D. EFFECT OF PYROGALLOL ON ALDEHYDE DEHYDROGENASE IN VITRO 
The elevation by PG of AcD levels in EtOH- or AcD-treated rats 
leads one to speculate that induction of EtOH catabolism or inhibition 
of AcD catabolism may be occurring, as discussed. Massive induction of 
ADH by PG in the one-hour pre-EtOH period seems highly unlikely, espe-
cially since added cofactor (NAD) would probably be required for such an 
occurrence. The induction of the catalase system of EtOH catabolism, 
perhaps by Hz02 generation, is unlikely, since pretreatment with the 
catalase inhibitor aminotriazole was reported not to change the effect 
of PG (Collins et al, 1974). PG has been seen, though, to be ·a H2o2-
generating compound (Heikkila, 1972), probably through the oxidation of 
two of its hydroxyl groups. This possibility requires examination, 
possibly by measurement of PG-derived H2o2 injection on EtOH-derived 
blood EtOH and AcD levels. The difficulty in the latter scheme would 
be in achieving high levels of H2o2 to simulate the proposed continuing 
generation of HzOz of PG, without reaching lethal levels of HzOz that 
might occur after a single large injection. 
The inhibition of aldehyde reductase seems an unlikely mechanism 
to be at w0rk, since the enzyme is found in low concentration in the 
liver and appears to contribute insignificantly to the overall metab-
olism of aldehydes in the body (Tabakoff and Erwin, 1970). However, under 
conditions of extremely high AcD levels such as those created by PG, 
aldehyde reductase may be playing a much larger role than normal. Pos-
sibly some of the EtOH levels seen after EtOH injection were derived 
from the AcD reverting to its precursor. But the absence of appreciably 
increased EtOH levels (Collins ~ al, 1974) following injection of PG 
and AcD argues against this. 
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studies in this study. Pyrogallol, similarly to propranolol (Duncan 1973), 
reversibly inhibited ALDH, giving mixed inhibition with respect to both 
aldehyde and NAD+cofactor. The nature of en~yme inhibition by PG has 
never been totally explicable, even in the well-known case of CA catab-
olism. Bacq (1936) originally attributed the NE pressor-potentiating 
properties of PG to its antioxidant properties. It is unlikely that anti-
oxidation is the means of inhibition of ALDH by PG, especially now that 
it has been shown that the commercial antioxidant, propylgallate, had no 
effect on ALDH activity. 
The report by Crout (1961) on COrIT inhibition by PG stressed 
that structural analogy, PG being a "double catechol11 in effect, did not 
explain the mixed competition that was observed. In vitro, competitive 
and partially non-competitive properties were seen. Inhibition of COMI' 
by PG preinjection lasted 30-60 minutes after a single injection of 200 
mg/kg, or even longer after several smaller doses every half-hour for 
several hours. 
In our work, the millimolar concentrations calculated for the 
ID50 values of pyrogallol and other compounds might be interpreted to 
indicate only weak inhibition of ALDH. However, millimolar levels of NAD 
and propionaldehyde were required in these experiments to achieve detec-
table rates, since pH7.0, used to prevent PG oxidation, has been shown to 
yield only one-fifth the activity seen at the optimal pH of 9.6-10.0 
(Erwin and Dietrich, 1966). Thus, the ID50 values for PG may be in the 
micromolar rather than millimolar range had micromolar concentrations of 
aldehyde been used, as in other studies (Duncan, 1973). This may explain 
the apparent discrepancy between the potent AcD-elevating effect of PG 
r 
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in vivo and its seemingly weaker ALDH inhibitory powe.r in vitro. 
PG is known to affect other enzyme systems (Webb, 1966), although 
the kinetics are usually not reported. Dehydroshikimate reductase from 
pea seedlings is inhibited by PG, as well as,by gallic and shikimic 
acids. Shikimic acid is non-aromatic but structurally similar to gallic 
acid. Shikimic acid showed no inhibition of ALDH in our study, possibly 
because of the carboxyl group or perhaps because the ring is cyclohexyl 
rather than phenyl, and the three hydroxyls are non-planar. 
The enzyme histidine decarboxylase from guinea pig kidney can 
also be inhibited by PG as well as by catechol, tyrosine, tryptophan, 
and DOPA. In that case, structural analogy seems to play very little 
part, especially since tryptophan and indole lack even the hydroxyl 
group of the other compounds. Finally, PG has been found to have a 
slight inhibitory effect on lamb kidney D-amino acid oxidase at concen-
trations where catechol,hydroquinone, and similar compounds served as 
stronger inhibitors. 
PG has been reported to cause striking hepatotoxicity in animals 
but the mechanism of this action is not quite clear (Webb, 1966) 
Very little else is known of the biochemical pharmacology of PG, 
but all facts should be recognized if ever therapeutic uses of this drug 
are proposed. The LD50 was calculated to be 566 mg/kg in normal mice, 
and 490 mg/kg in hyperthyroid mice (Webb, 1966). Since thyroid hormones 
have been found to be COMT inhibitors in vitro (D'Iorio, 1963), perhaps 
their increased levels in hyperthyroidism cause an inhibition of PG 
methylation by COMT, thus increasing PG half-life and toxicity. PG is 
also known to act as a mitotic inhibitor of oligochaete cleavage, the 
mechanism of which is unclear, but the same property belongs to others 
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with quinone structures. In fact, many of the physiobiochemical effects 
of PG have not been studied directly but can only be inferred from known 
properties of quinones, benzoquinone (called hydroquinone in reduced 
form) being the most commonly tested. 
The methemoglobinemia induced by quinones significantly in vitro 
is insignificant in vivo, implying that erythrocytes can reduce quinones 
effectively (Webb, 1966). Apparently, then, the darkened blood observed 
after PG injection of rats in these experiments was due to products of 
PG or to some mechanismcther than methemoglobinemia. 
Oxidative phosphorylation is inhibited by various quinones, but 
little evidence is available as to whether electron shunts, phosphorus 
transfer, quinone displacement, or sulfhydryl reaction is the mechanism 
responsible. Although the vitamins K belong to the quinone family, none 
of the PG-related quinones have been seen to inhibit vitamin K synthesis 
(Webb, 1966). Such bleeding difficulties, even had they been inductible 
by PG, would have had little bearing on the short-term experiments done 
in this study. 
In animals, the CNS stimulation by quinones is followed by 
depression of the CNS and of respiration (Webb, 1966). This resembles 
the effect of PG, that of pressor response soon followed by tachyphylaxis 
(Wylie~ al, 1960). It is possible that some of the physiologic 
darkening of the blood in rats treated with PG was due to cyanosis sec-
ondary to respiratory depression. It was noted that the rate of respira-
tion seemed to be increased, but quantitation of the respiratory depth 
was not done. Unlike animals, humans who have overdosed with catechol, 
hydroquinone, and others, show only depression with no initial stimula-
tion. This depression has been found not to be the result of asphyxia, 
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methemoglobinemia, or hypoglycemia (Webb, 1966). As can be seen, much 
work on the pharmacology of the quinones and of PG in particular needs 
to be perfonned. 
The compound RO 4-4602, very important in Parkinson's disease 
therapy as a decarboxylase inhibitor and also shown to be a COM!' inhib-
itor (Baldessarini, 1972), has now been shown to be an in vitro ALDH 
inhibitor of approximately equivalent strength to pyrogallol. The 
presence of the gem-trihydroxybenzene nucleus of both drugs may account 
for their similar actions. The lesser AcD-potentiation in vivo caused 
by RO 4-4602 compared to PG (unpublished results), may be due .to more 
rapid catabolism, excretion, or distribution of RO 4-4602, due to the 
serylhydrazine residue. RO 4-4602 was one of only three compounds that 
affected both AcD levels in vivo and ALDH activity in vitro, the others 
being pyrogallol and diethyldithiocarbamate. Several compounds had in 
vitro but not in vivo effects at the concentrations tested, including 
hydroquinone, 3-methoxycatechol, and gallic acid, while the in vitro 
inhibitor 1,2,4-trihydroxybenzene, was not tested in vivo, but 6-hydroxy-
DA was tested (The 1,2,4-trihydroxybenzene moiety is present) and 
caused no increases in blood AcD in EtOH intoxicated rats (Collins ~ al, 
1974). Interestingly, all in vivo AcD-potentiators were found to have 
ALDH inhibitory powers in vitro (Table 9). However, the order of po-
tency in vivo did not correspond to the in vitro strengths. 
From the results of these experiments, the PG-induced enhance-
ment of pressor responses to CAs may now be thought of as arising from two 
possible actions of PG: COMT inhibition and ALDH inhibition. Increased 
levels of biogenic amine-derived aldehydes may be induced by PG admin-
istration. It has been suggested that these aldehydes have pharmacol-
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ogic properties of their own (Sabelli and Giardina, 1971; Barondes, 1962) 
through (a) release of stored amines, (b) shifts in metabolic pathways, 
(c) incorporation into storage vesicles, (d) condensation with endogenous 
amines. Thus, some of the pharmacologic actions of PG may be mediated 
by certain endogenous aldehydes. 
It is possible that a non-toxic PG containing compound similar to 
RO 4-4602 could be employed by clinical investigators as substitutes for 
disulfiram (Antabuse) therapy in alcoholics. Various toxic manifestations 
of Antabuse treatment (Fox, 1973), including death, may be reduced by 
using a different inhibitor of ALDH. 
Another likely use for PG is in experiments where condensation 
products of aldehydes and CAs (e.g. tetrahydroisoquinolines or TIQs) are 
sought after EtOH administration. By maximizing levels of TIQ precur-
sors, e.g. Norepinephrine and AcD, while simultaneously blocking 0-methyl-
ation of the TIQs, levels of TIQs in tissues may be raised to increase 
the ease of their detection. In fact, such experiments utilizing the 
twin actions of PG have already been reported (Collins and Bigdeli, 1974). 
E. CHRONIC ALCOHOL DRINKING MODELS 
1. MOUSE EXPERIMENTS 
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The intoxicating effects of the EtOH-Metrecal protocol on male 
mice indicated that these animals appeared more susceptible to the ef-
fects of EtOH than were female mice or male rabbits. The withdrawal 
effects, however, were less marked than were those seen by Freun:l.These 
discrepancies might be attributable to strain or sex differences, or to 
specific factors associated with feeding. 
First of all, clogging of the metal tubes, through which mice 
drank from inverted glass bottles, appeared to be a factor.The .sediment 
from Metrecal, although prepared fresh and shaken well, often clogged 
the tube and starved the animals, in effect, until the next feeding the 
following morning. Examination of the bottles at 12 A.M. to 2 A.M. on 
various nights still did not prevent this occurrences. Thus, animals 
may not have drunk as much as they would have without clogging. Freund 
did not report such a complication in his study. This problem may have 
led to some of the deaths seen during EtOH drinking, especially in mice 
that were found dead with hind limbs extended, which according to 
Freund, denotes death during convulsion. Use of larger bore feeding 
tubes did not decrease the clogging, even in our rabbit experiment, so 
open pottery crocks were used with the rabbits. 
A second factor contributing to our lack of success with intox-
ication and withdrawal signs in mice may well be that we, as well as . 
Freund, were observing effects of Metrecal toxicity or of malnutrition. 
This factor has been examined by Mendelson. Data leading to this 
conclusion include the facts that (a) mice were dying during the weight 
reduction, (b) more mice died during EtOH drinking, possibly due to the 
r 
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combined effects of weight reduction and EtOH, (c) EtOH drinkers contin-
ued to lose weight while the isocaloric sucrose group gained almost 20% 
more than the EtOH group, and (d) EtOH drinkers consumed only 50% of the 
volume, and therefore of the calories, of their sucrose counterparts. 
These data lead to the conclusions that (a) drastic weight reduction 
should be avoided, (b) pair-fed controls are required to rule out caloric 
discrepancies, and (c) some of the behavioral effects attributed to EtOH 
in our experiment may be due to toxicity of Metrecal or to malnutrition, 
as has been suggested by Mendelson (1971). 
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2. RABBIT EXPERIMENTS 
Although the number of rabbits used (3 ethanol, 3 sucrose) is 
limited, several observations can be made regarding the feasibility of 
this ethanol-Metrecal diet in rabbits. 
Four factors in the design of this experiment ~re worthy of note: 
(1) The choice of either alcohol drinking or starvation, rather than 
force-feeding, was implemented. This may allow various systems within 
the animal to regulate its alcohol and caloric intakes. Thus, the human 
alcoholic pattern is more closely approximated. Further, the occurrence 
of gastrointestinal ulcerations and other results of force-feeding may be 
avoided, but the question of alcohol preference was begged in this protocol. 
(2) Pair-fed controls were used to eliminate the effects of malnutrition 
often seen from depression of appetite by ethanol. The importance of 
pair-feeding is demonstrated in Freund's report on the mouse-Metrecal 
model, wherein animals on the ad lib ethanol diet drank less than one-half 
the amount of fluid as those drinking isocaloric sucrose ad lib (Table 12). 
This fact, on top of the 20% weight reduction effected in Freund's mouse 
experiments, possibly contributed to the intoxication and withdrawal 
effects, even though, as Freund notes, the clinical symptomatology induced 
by extreme starvation is quite different from the ethanol withdrawal syn-
drome. In our study, ethanol and sucrose groups were control-fed not 
only for caloric concentrations, but for total daily caloric in-take as well. 
(3) A possible weak point in our study may be the massive concentration 
of ethanol attained in the experimental diet. The gradual increase from 
6% to 20% v/tv ethanol was instituted because no significant gross 
intoxication was observed at the lower ethanol concentrations. It is 
still possible that behavioral alterations did occur at night while the 
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animals were not watched. However, the ability to catabolize ethanol 
and acetaldehyde seemed to be accelerated in ail ethanol-treated animals 
as evidenced by the cyclical blood level curves of these compounds, 
despite increasing intake, at all but the two highest concentrations of 
diet ethanol (Fig. 9). Even these high conc~ntrations failed to produce 
intoxication. Apparently, enhanced EtOH metabolism and/or possible ad-
aptation of the nervous system may have prevented gross behavioral changes. 
(4) Large pottery bowls were used as food containers rather than glass 
bottles or cylinders with steel drinking tubes. The latter, in our hands, 
had a great tendency to clog up due to the sedimentation of particles 
from the chocolate Metrecal itself. In the experiments with mice, this 
clogging may have resulted in several deaths from either starvation or 
alcohol withdrawal. The large surface area of the pottery bowls was not 
seen to increase evaporation of ethanol, since less than 2% evaporation 
of ethanol in 24 hours was observed when the supernatant of the 500 xg 
centrifugate was assayed by gas chromatography. 
The pathological changes in the animals brought up the possibil-
ity of nutritional deficiencies and/or toxicity of Metrecal itself. The 
lack of normal weight gain and the loss of body hair throughout the exper-
imental period occurred in both the ethanol and sucrose groups. This 
points to the lack of proper nutrients for rabbits in this diet protocol. 
The severely fatty livers seen only in the ethanol group indi-
cates the role of alcohol, and not of malnutrition, in producing such 
fatty change. Ruebner et al (1972) also found that substitution by 
isocaloric carbohydrates for ethanol did not reproduce the fatty livers 
in monkeys fed Freund's diet at a diet ethanol concentration of 7.9% 
r 86 v/tv. In addition, choline supplements to the diet in Ruebner's work 
did not reverse the fatty changes, suggesting that these changes are not 
due to the lack of lipotropic factors or to dietary imbalance, but to 
EtOH itself. 
The single death that occurred four days before the end of the 
study was that of a sucrose control animal. This further implicates the 
lack of proper nutrients for rabbits in this diet, especially when daily 
volumes are limited by pair-feeding. The liver of this dead animal 
appeared no different from those of the other animals in the sucrose 
group, indicating that the cause of death was not reflected in the cyto-
architecture of the liver by light microscopy. It is possible, though, 
that further deaths in both experimental and control animals may have 
occurred had the length of the study been extended. It is also possible 
that EtOH served some protective function in animals imbibing it, thus 
prolonging their lives. It was not clear whether the single death 
resulted from: 
(1) Prolonged nutritional deficiency from the composition or amount of 
the diet; 
(2) Possible hepatotoxicity of Metrecal as suggested by Mendelson, which 
was not noticeable by light microscopy· in our study, but may still be 
contributory; 
(3) An illness unrelated to diet; 
(4) The last factor, the absence of bulk, may be underscored by citing 
the percent fiber found in Purina Lab Chows for mice (3.8%) versus that 
for rabbits (14.6%) (Purina, 1972). The lack of fiber in a liquid diet 
may lead to abnormalities of digestive processes upon which proper 
nutrition depends. 
l 
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Ethanol and acetaldehyde blood levels in rabbits were hard to 
compare to those of other studies, primarily because of the differences 
in dose, species, age, sex, route of aministration, and other factors. 
The blood levels in our studies usually were in the range of 0-100 mg% 
EtOH and 0-9 pg/ml AcD. Majchrowicz (1973), feeding EtOH to rats by 
intragastric intubation for up to eight days, showed that blood EtOH and 
AcD concentrations ranged frcm 100-500 mg% and l-3pg/ml, respectively. 
Freund's mice reached blood levels of EtOH of at least 400 mg% while 
drinking EtOH-Metrecal ad lib for five days. Very few EtOH metabolism 
experiments with rabbits, however,.have been reported. Duritz and Truitt 
(1966) observed peak blood EtOH and AcD levels of 380 mg% and 4f1g/ml, 
respectively, after acute EtOH injection (4.0 g/kg i.v.) in rabbits. 
Both the rate of alcohol metabolism and the range of blood alcohol 
concentrations were lower in rabbits than in rats and mice in a study 
cited by Israel and Mardones (1971). These authors calculated rabbit 
EtOH metabolism to be less than one-third that of rats and the blood 
alcohol was found to range from 30-100 mg% under conditions that gave 
rats levels of 0-300 mg%. 
Blood AcD concentration seemed to be related to blood EtOH levels 
in our rabbits, but other investigators (Mello and Mendelson, 1970) found 
no dose or dose-time relationship between blood EtOH and blood AcD, and 
also saw that mean blood AcD concentrations were relatively constant 
through all dose ranges of EtOH, possibly due to rapid induction of ALDH. 
Lack of gross intoxication in our animals, even with high blood 
EtOH levels, may involve enhanced EtOH metabolism by the liver or by the 
nervous system. Raskin and Sokoloff (1972) have demonstrated a minute 
amount of alcohol dehydrogenase in the rat brain which undergoes an 
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adaptive increase in its activity during chronic EtOH ( 20 days) 
ingestion .. In human alcoholics studied by Mello and Mendelson (1970), 
blood alcohol level was rarely found to be an adequate predictor of 
behavior~ possibly inferring nervous system adaptation. 
Relatively similar blood AcD and EtOH levels despite increasing 
EtOH consumption may be related to an increase in the rate of EtOH metab-
olism, although this effect is still controversial, as indicated in a 
review by Hawkins and Kalant (1972). These au tho rs point to two proces-
ses that may be involved in the effect of prolonged EtOH intake on the 
levels of liver alcohol dehydrogenase: an adaptive process involving a 
specific induction of ADH, and a non-specific decrease of enzyme levels 
as a manifestation of depressed protein synthesis resulting from liver 
impairment. 
The three-month duration of this experiment may contribute to 
some of our findings, since the age of the animal is known to influence 
the blood EtOH concentration and the rate of its disappearance. These 
differences apparently are not due to altered liver ADH activity, but 
may be caused by age-dependent changes that may alter the compartmental-
ization (e.g. body fat) NAD/NADH2 ratios, or rate of metabolism of EtOH 
by processes other than ADH (Hollstedtand Rydberg, 1970). The very high 
levels of EtOH and AcD seen near the end of the experiment, however, may 
well be due to general debilitation caused by prolonged malnutrition. 
Further, malnutrition states, such as ascorbic acid deficiency, are known 
to themselves contribute to changes in A.DH and NAD/NADH2 ratios (O'Keane 
et al, 1972) 
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F. SUMMARY 
These studies have uncovered the important role of PG as a dual 
enzyme inhibitor, favoring catecholamine-derived isoquinoline formation 
in in vivo studies. The first report of gas chromatographic evidence of 
isoquinoline biosynthesis after ethanol intoxication (Collins and Bigdeli, 
1974) has recently emerged. These authors utilized the effects of PG 
revealed in the present studies. 
Pyrogallol can now be postulated to enhance isoquinoline levels 
in vivo through at least three biochemical mechanisms, two of which were 
demonstrated for the first time in these studies: 
(1) The oxidation of acetaldehyde via aldehyde dehydrogenase is 
inhibited, thus maximizing concentrations of one isoquinoline precursor. 
(2) The 0-methylation and possibly inactivation of isoquinolines 
are decreased. 
(3) Combined with the well-known inhibition by pyrogallol of the 
catechol 0-methyltransferase degradation of norepinephrine and dopamine, 
these first two effects lead to elevated isoquinoline levels and maximal 
possibility of detection. 
Compounds structurally related to PG were found to inhibit 
aldehyde dehydrogenase in vitro _and elevate ethanol derived acetaldehyde 
levels in vivo, properties which may lend these drugs to clinical applica-
tion as disulfirarn~lile deterrents in alcoholics. 
Animald models of chronic alcoholism using a liquid (Metrecal) 
diet were anernpted. This protocol pro.duced intoxication and slight 
withdrawal symptoms in mice. Rabbits, despite developing elevated blood· 
acetaldehyde and ethanol concentrations, displayed virtually no gross 
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intoxication while demonstrating fatty liver changes. Malnutritional 
aspects of this diet were possible.factors contributing to the pathologies 
seen. 
r 
l 
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TABLE 1 
Composition of liquid diet* 
EtOH (95%) Metrecal Sucrose 87% w/tv Water added 
v/tv cal/ml diet 
EtOH 6 35 61 65 33 0.9 
Sucrose __ 61 65 9 35 30 0.9 
*Freund, 1969. Diet used in this study with mice and initially with 
rabbits. 
r 
TABLE 2 
Maximal Stages of Intoxication and Withdrawal reached 
in mice 
No. mice 
Intoxication J.R. Freund 
1. ataxic, but rapid gait 12/48 0/10 
2. between 1 and 3 25/48 5/10 
3. coma, no righting reflex 11/48 5/10 
Withdrawal 
1. overactivity, tremors 6/28 0/10 
2. tail-beating, tail-to-nose, 2/28 3/10 
retropulsion, broad gait, 
stereotypy 
3. tonic-clonic convulsion 1/28 6/10 
4. deatr during convulsion 0/28 1/10 
J.R.= results of present study 
Freund= results of G. Freund (1969) 
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TABLE 3 
Reaction times of NE and EPl with aldehydes to form TIQs, 
determined by iodochrome monitoring 
Reaction time (min) 
HCHO 
NE 20 5 
EPl 35 7 
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TABLE 4 
Rf values for NE an<l NE-derived TIQs by thin-layer 
chromatography in two solvent systems 
System A System B 
NE 0.40 0.22 
NM 0.46 0.31 
TIQ I 0.33 0.29 
6-0-Me-TIQ I 0.43 0.26 
TIQ II 0.18 0.21 
6-0-Me-TIQ II 0.28 0.27 
System A: sec-butanol:formic acid: water (15:3:2), 
Adsorbosil-1 TLC plate 
94 
System B: methanol:n-butanol:benzene: water (40:30:20:10), 
cellulose MN 300 plate 
,......-
TABLE 5 
Effect of Pyrogallol on the 0-methylation of Noradrenaline and two tetrahydroisoquinoline 
derivatives in rat brain and liver homogenates 
~rain Liver 
3H-Compound % 0-Methylation* % Inhib. due % 0-Methylation* % Inhib. due 
Saline · ··PG ·· to PG Saline PG to PG 
(5)~'c* 33.6 :!:" 4.6a + 53.9 35.3 :!:" 4.6b,c + 50.2 NE 15 .5 - 3.0 17.6 - 3.4 
TIQ I (8) 21.5 :!:" 6.la + 2.0 - 1.0 90.7 78.2 ± 8.3b,d + 31.0 - 4.6 60.4 
TIQ II (8) + 29.3 - 4.5 + 7.9 - 3.2 73.l 58.l "t 4.5c,d + 6.2 - 5.1 89.4 
* Per cent of added substrate that was 0-methylated, out of total radioactivity, corrected for 
recovery, ( recovery= 70 ± 5 per cent). Results expressed as mean: S.D. 
**Number of determinations for each saline and each PG experiment in parentheses. 
Statistical significance by student's unpaired t-test: 
a - p < 0.005 
b, c,d - p < 0.001 
--"'~~ 
\0 
\JI 
,.... 
TABLE 6 
Effect of PG on EtOH-derived AcD and EtOH blood levels (pg/ml) 
Saline 
EtOHb 
PG 
EtOHb Time(min) AcDa AcDa 
30 + 1.2 - 0.3 1200 t 300 + 2.0 - 0.8 1000 ~ 300 
60 + 2.6 - 0.5 1600 t 330 + 4.8 - 1.2 1900 : 550 
120 + 2.0 - 0.4 1700 t 400 + 4.1 - 1.6 1900 ":!:" 470 
180 + 1.0 - 0.2 1200 : 380 + 3.6 - 1.2 1300 t 410 
270 + 0.3 - 0.1 650 : 220 + 1.9 - 0.4 600 ':!_- 280 
360 + 0.1 - 0.1 300 ~ 200 + 0.5 - 0.3 450 :- 210 
Each figure represents mean ":!:" S.D. of 4 rats following PG (250 mg/kg i.p.) 1 hour before EtOH (2.0 g/kg 
i.p.) 
a p < 0.05, PG compared to saline, at 60, 120, 180 and 270 min. 
b N.S. at any time, PG-compared to saline. Student's unpaired t-test. 
\0 
°' 
-, 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
(7) 
(8) 
(9) 
(10) 
(11) 
(12) 
97 
TABLE 7 
Reversibility and deletion controls in studies on the effect of 
PG on Al.DH activity 
Conditions Pre-Incubation with 
PG 
NAD, Enz, Prop. 
(1) plus PG3 3 
II II 
" 5 
" 
II II 10 
II 
" " 15 
NAD, ~nz. 
NAD, Prop. 
Enz., Prop. 
NAD, Enz., PG 3 
NAD, Prop., PG 3 
Enz • , Prop • , PG 3 
PG-Enz.,aliquot4 3 
1 moles NADH/min/mg protein xlo-11 
2 Enz.= enzyme, Prop.= propionaldehyde 
3 PG = pyrogallol, 10-4 M 
4 Reversibility experiment (see text) 
Activity 
12.5 
6.3 
6.3 
6.3 
6.3 
0.5 
0.2 
o.o 
0.3 
0.1 
o.o 
6.3 
r 98 
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TABLE 8 
Effect of pyrogallol and related compounds on in vitro 
activity of rat liver mitochondrial aldehyde dehydrogenase 
COMPOUND M x 10-4 ACTIVITY % INHIBITION 
Pyrogallol (PG) 0 12.5 0 
0.5 11. 7 6.4 
5.0 8.8 27.0 
10.0 6.3 49.5 
1,2,4-Trihydroxybenzene 0.5 7.7 38.5 
5.0 6.3 49.5 
10.0 s.o 60.0 
Hydroquinone 0.5 9.3 26.2 
5.0 7.3 41.9 
10.0 5.8 54.1 
RO 4-4602 0.5 11.8 5.4 
5.0 8.0 36.8 
10.0 6.5 46.0 
Diethyldithiocarbamate (DDC) 0.5 11.6 6.8 
5.0 9.2 26.7 
10.0 8.3 33.3 
3-Methoxycatechol 0.5 12.5 0 
5.0 10.3 17 .2 
10.0 8.6 31.4 
Gallic Acid 0.5 12.5 0 
5.0 12.5 0 
10.0 10.6 15.6 
2,3-Dimethoxyphenol 0.5 12.5 0 
5.0 12.0 4.3 
10.0 11.6 6.9 
Propylgallate 0.5 12.5 0 
5.0 12~5 0 
10.0 11. 7 6.2 
d,1-Shikimic Acid 0.5 12.5 0 
5.0 12.5 0 
10.0 12.l 3.4 
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TABLE 8 (continued) 
M x 10-4 ACTIVITY % INHIBITION 
3,4-Dihydroxytoluene 0.5 12.5 0 
5.0 12.5 0 
10.0 12.5 0 
Tetrahydroxyquinone 0.5 12.5 0 
5.0 12.5 0 
10.0 12.5 0 
TABLE 9 
Comparison of in vitro ALDH inhibition and in vivo poten-
tiation of EtOH- derived AcD blood levels. 
Category Compound In vitro In vivo* 
1 PG + + 
2 DDC + + 
1,3 RO 4-4602 + + 
4 1,2,4-trihydroxybenzene + ** 
4 Hydroquinone + 0 
5 3-methoxy-Catechol + 0 
5 2,3-dimethoxy phenol 0 0 
4 Gallic acid 0 0 
* Collins et al, 1974. 
** Lethal at dose used for other compounds. 
In vitro= + = inhibits ALDH over 15% at 5 x 10-4 M. 
In vivo= + = increases blood AcD post-injection of EtOH (3g/kg) 
compared to saline. 
Categories: 
l= COMT inhibitor; 2=ALDH inhibitor; 3= DOPA decarboxylase 
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inhibitor; 4= similar structure to PG; 5= product of COMT action on PG 
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TABLE 10 
Weight change of rabbits drinking Metrecal diets 
DIET % change from initial Average Group 
weight change 
EtOH + 5 -0.67 ~ 2.94 
II 
-10 
II + 3 
Sucrose + 7 + +6.33 - 0.94 
II + 7 
II + 5 
Lab chow +73 +73.0 + - 0.00 
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' TABLE 11 
Animal deaths during chronic alcohol experiments 
Mice Rabbits 
Weight-reduction 5/180 
EtOH-drinking 8/ 80* 0/3 
Withdrawal 0/ 28 
Sucrose-drinking 0/ 20 1/3 
* 3 died with limbs extended, possibly denoting convulsions. 
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TABLE 12 
Weight change in mice during Metrecal diets 
Diet {with Metrecal} fa change from initial weight* {Ave.2 
Sucrose-(n=29) + 14.6 + 4.2 -
EtOH - (n=42) 4.4 + 2.9 
* following 9 days of weight reduction 
p < 0.01, student's unpaired t-test 
.. 
r 
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TABLE 13 
Daily volume of Metrecal diet consumed ad. lih. by mice 
Diet 
Sucrose (n=29) 
EtOH (n=42) 
Volume, ml (aver., 5 days) 
16.3 + 2.1 
8.2 t 3.7 
p < 0.01, Student's unpaired t-test. 
Values expressed as average± S.D. 
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TABLE 14 
EtOH consumption pattern of rabbits 
% EtOH (v/v) % total calories Days at EtOH consumption, 
from EtOH this level ml (average, n=3) 
6.0 35 12 15.8 
7.5 39 4 21.9 
10.0 46 19 26.7 
12.5 54 10 25.8 
15.0 59 10 25.0 
17.5 63 6 27.1 
20.0 71 19 29.1 
r 
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TABLE 15 
Physical effects of liquid diet on rabbits 
EtOH 
Sucrose 
Lab Chow 
Hair loss 
2/3 
2/3 
0/1 
Death 
0/3 
1/3 
0/1 
Weight change %* 
- 1 
+ 7 
+ 73 
* Per cent of weight at start of diet administration. 
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TIQ II 
FIG. 1. Condensation of norepinephrine with aldehydes to form 
tetrahydroisoquinoline alkaloids. 
NE=norepinephrine, AcD=acetaldehyde, HCHO=formaldehyde, 
TIQ=l,2,3,4-tetrahydroisoquinoline. 
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FIG. 2. Gas chromatogram of air, water (HzO), acetaldehyde (AcD), 
ethanol (EtOH) and acetone, using Porapak Q-S column in 
Varian 2100 gas chromatograph. 
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products formed, out of total recovered radioactivity. 
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FIG. 4. Metabolism of TIQs in rat brain homogenate 
Results expressed in terms of percent non-catechol (O-methylated) 
products formed, out of total recovered radioactivity. 
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FIG. 5. Calibration curve for EtOH and AcD in whole blood determined 
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Peak heights expressed in divisions on recording paper (n=4 per point) 
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FIG. 6. Representative spectrophotometric recording in aldehyde 
dehydrogenase assay. 
S= substrate alone added; S + I = substrate plus inhibitor; 
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I= inhibitor alone added; B= blank control, no substrate or inhibitor 
added. Absorbance is expressed in optical density units at 340 run. 
Time scale is 2 min. Total. 
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FIG. 7. Double reciprocal plot of the inhibition of rat liver mito-
chondrial ALDH by PG with respect to NAD cofactor • 
PG concentrations: 8, none; • 100 fM; .._ , 500 JIM· 
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FIG. 8. Double reciprocal plot of the inhibition of rat liver mito-
chondrial ALDH by PG, with respect to the substrate propion-
aldehyde. 
PG concentrations: •, none: • , 100 FM; .A. , 500 pM. 
PROP= propionaldehyde. 
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FIG. 9. Ethanol and acetaldehyde blood levels and daily ethanol 
consumption in a representative rabbit drinking Metrecal/ 
ethanol. 
/\ indicates increased ethanol concentration in diet 
(6.0, 7.5, 10.0, 12.5, 15.0, 17.5, and 20.0 % v/v, respectively). 
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FIG. 10. Analogous metabolism by COMT of NE and NE-derived TIQs, 
inhibitable by PG. 
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R= H or CH3 ; NE= norepinephrine; NM= normetanephrine; COMT= catechol 0-methyltransferase; PG= pyrogallol; TIQ= 1,2,3,4-tetrahydroisoquinoline. 
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FIG. 11. Effect of pre-injection of PG or saline on AcD disappearance 
in rat liver homogenate. 
Doses: PG 250 mg/kg or saline 0.9%, 1 ml i.p. 1 hr. pre-sacrifice. 
Homogenate: 1 ml rat liver homogenate 1:1 in pH 7 pyrophosphate buffer. 
AcD 0.33 mM and NAD 0.33 mM added. 
Peak heights expressed in cm. as mean± S.D. (n=3). 
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FIG. 12. Structures of PG and related compounds tested for effect on 
in vitro activity of rat liver mitochondrial ALDH. 
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FIG. 13. Liver section of rabbit after 80 days of EtOH/Metrecal diet, 
showing abundant fat vacuoles. 
FIG. 14. Liver 
diet, 
fatty 
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section of rabbit after 80 days of Sucrose/Metrecal 
showing relatively normal cell structure with slight 
changes. 
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ABBREVIATIONS 
acetaldehyde 
alcohol dehydrogenase 
aluminum hydroxide 
aldehyde dehydrogenase 
adenosine triphosphate 
catecholamine 
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cyclic adenosine 3' ,5'-monophosphate 
catechol 0-methyltransferase 
dopamine 
dopamine beta-hydroxylase 
diethyldithiocarbamate 
dihydroxyphenylalanine 
disulfiram 
epinephrine 
ethanol 
gram 
formaldehyde 
hour 
serotonin (5-hydroxytryptamine) 
potassium 
kilogram 
monoamine oxidase 
magnesium 
milligram 
minute 
ml 
Na 
NE 
0-Me-TIQ 
PG 
PNMT 
SAM 
TH 
THP 
TIQ 
TIQ I 
TIQ II 
ABBREVIATIONS (continued) 
milliliter 
sodium 
norepinephrine 
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6-0-methylated form of corresponding TIQ 
pyrogallol 
phenylethanolamine N-methyltransferase 
S-adenosylmethionine 
tyrosine hydroxylase 
tetrahydropapaveroline 
tetrahydroisoquinoline 
l-methyl-4,6,7-trihydroxy-TIQ 
4,6,7-trihydroxy-TIQ 
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